Mins 09060810 Ohio State Board of Pharmacy Minutes, Courtesy of Lindon & Lindon

Note: These Minutes are provided for informational purposes only.
If you would like to obtain an official copy of the Minutes, please contact
the State Board of Pharmacy at 614-466-4143 for instructions and fee information.
Ohio State Board of Pharmacy 77 South High Street, Room 1702 Columbus, Ohio 43215-6126
telephone: 614-466-4143 fax: 614-752-4836 email: exec@bop.state.oh.us
Minutes of the June 8-10, 2009

Meeting of the Ohio State Board of Pharmacy
Monday, June 8, 2009
10:00 a.m. The Ohio State Board of Pharmacy convened in Room East B, 31st Floor, of the Vern Riffe
Center for Government and the Arts, 77 South High Street, Columbus, Ohio, with the following
members present:
Nathan S. Lipsyc, R.Ph., President; Elizabeth I. Gregg, R.Ph., Vice-President; Donald M.

Casar, R.Ph.; Barton G. Kaderly, Public Member; Richard F. Kolezynski, R.Ph.; Deborah A.
Lange, R.Ph.; Heather L. Pasquale, R.Ph.; and Jerome J. Wiesenhahn, R.Ph.
Also present were William T. Winsley, Executive Director; Mark Keeley, Legislative Affairs
Administrator; Chris Reed, Compliance Supervisor; David Rowland, Legal Affairs
Administrator; Danna Droz, Prescription Drug Monitoring Program Director; and Tracy
Marie Greuel, Assistant Attorney General.
10:02 a.m. Mrs. Gregg moved that the Board go into Executive Session for the purpose of the investigation
of complaints regarding licensees and registrants pursuant to Section 121.22(G)(1) of the Ohio
Revised Code and to confer with an attorney for the Board regarding pending or imminent court
action pursuant to Section 121.22(G)(3) of the Ohio Revised Code. The motion was seconded
by Mr. Wiesenhahn and a roll-call vote was conducted by President Lipsyc as follows: Casar –
yes; Gregg – yes; Kaderly – yes; Kolezynski – yes; Lange – yes; Pasquale – yes; and
Wiesenhahn – yes.
10:16 a.m. Mr. Braylock arrived and joined the meeting in progress.
1:23 p.m. The Executive Session ended.
The meeting was recessed for lunch.
2:15 p.m. The Board reconvened with all members present.
R-2009-276 After discussion, Mr. Wiesenhahn moved that the exam extension request from pharmacy
intern Cheryl Hutchins (03-2-16453) Cincinnati, Ohio, be granted. Mrs. Gregg seconded the
motion and it was approved by the Board for 90 days: Aye –7; Abstain – 1 (Braylock).
R-2009-277 After consideration, Mrs. Gregg moved that the Board Order issued to Raymond Denuit, R.Ph.
(03-1-10793) Oak Hill, Ohio, on April 8, 2009, be rescinded and a new Order issued. The
motion was seconded by Ms. Pasquale and approved by the Board: Aye –7; Abstain – 1
(Braylock).
After votes were taken in public session, the Board adopted the following order in the matter of
Raymond Denuit, R.Ph. (03-1-10793).
2 of 154
ORDER OF THE STATE BOARD OF PHARMACY

Docket Number D-090204-085
in the matter of:
RAYMOND P. DENUIT, R.Ph.

240 North Street
Oak Hill, Ohio 45656
R.Ph. Number 03-1-10793
INTRODUCTION
The matter of Raymond P. Denuit came for hearing on April 8, 2009, before the
following members of the Board: Elizabeth I. Gregg, R.Ph, (presiding); Gregory
Braylock, R.Ph.; Donald M. Casar, R.Ph.; Barton G. Kaderly, Public Member;
Richard F. Kolezynski, R.Ph.; Deborah A. Lange, R.Ph.; and Jerome J.
Wiesenhahn, R.Ph.
Nathan S. Lipsyc, R.Ph., Board President, absent
Heather L. Pasquale, R.Ph., Board Member, absent
Raymond P. Denuit was represented by Elizabeth Y. Collis. The State of Ohio

was represented by Tracy Marie Greuel, Assistant Attorney General.
SUMMARY OF EVIDENCE
State’s Witnesses; Kevin J. Kinneer, Ohio State Board of Pharmacy

Rachel Carver, CVS
Raymond Denuit, R.Ph., Respondent
Respondent's Witnesses: None
State's Exhibits:
1. Copy of Notice of Opportunity For Hearing letter [02-04-09]
1A-1D. Procedurals
2. Notarized Statement of Rachel L. Carver [02-26-08]
3. Statement of R. Denuit [not dated]
4. Notarized Statement of Ray Denuit [03-16-08]
5. Six Color Photographs [04-20-09]
Respondent's Exhibits:
A. Letter from Stephen E. Palmer Esq., To Elizabeth Y. Collis, Esq. [04-07-09]
B. Letter of Support [not dated]
C. Letter from Eric Lambert, R.Ph. to Ohio State Board of Pharmacy [04-01-09]
FINDINGS OF FACT
After having heard the testimony, observed the demeanor of the witnesses,
considered the evidence, and weighed the credibility of each, the State Board of
Pharmacy finds the following to be fact:
(1) Records of the State Board of Pharmacy indicate that Raymond P. Denuit
was originally licensed in the State of Ohio on July 30, 1974, pursuant to
3 of 154
examination, and is currently licensed to practice pharmacy in the State of

Ohio.
(2) Raymond P. Denuit did, on or about April 20, 2007, have sexual contact with
another, not his spouse, knowing that the sexual contact was offensive or
being reckless in that regard, to wit: Raymond P. Denuit fondled the breast of
a pharmacy store-front employee when the conduct was not invited and was
offensive. Such conduct is in violation of Section 2907.06(A)(1) of the Ohio
Revised Code.
(3) Raymond P. Denuit did, on or about March 11, 2008, knowingly make a false
statement with purpose to mislead a public official in performing the public
official’s official function, to wit: Raymond P. Denuit lied to Board agents who
were investigating his actions involving a pharmacy store-front
employee. When confronted with verbal accounts of his actions, physical
evidence documenting the same, and his own statement previously made,
Raymond P. Denuit lied to the Board agents so as to exonerate himself and
end their investigation. Such conduct is in violation of Section 2921.13(A)(3)
of the Ohio Revised Code.
(4) Raymond P. Denuit did, on or about March 11, 2008, fail to cooperate with a
Board investigation and Raymond P. Denuit failed to divulge all relevant
information when requested by Board agents. Specifically, Raymond P.
Denuit tried to mislead the agents and he lied to them about the underlying
facts in their investigation, thereby Raymond P. Denuit failed to cooperate in
the investigation. Such conduct is in violation of Section 4729.19 of the Ohio
Revised Code.
CONCLUSIONS OF LAW
(1) The State Board of Pharmacy concludes that paragraphs (2) through (4) of
the Findings of Fact constitute being guilty of gross immorality as provided in
Division (A)(1) of Section 4729.16 of the Ohio Revised Code.
(2) The State Board of Pharmacy concludes that paragraphs (2) through (4) of
the Findings of Fact constitute being guilty of unprofessional conduct in the
practice of pharmacy as provided in Division (A)(2) of Section 4729.16 of the
Ohio Revised Code.
(3) The State Board of Pharmacy concludes that paragraph (4) of the Findings of
Fact constitutes being guilty of willfully violating, conspiring to violate,
attempting to violate, or aiding and abetting the violation of provisions of
Chapter 2925. of the Revised Code as provided in Division (A)(5) of Section
4729.16 of the Ohio Revised Code.
DECISION OF THE BOARD
Pursuant to Section 4729.16 of the Ohio Revised Code, and after consideration
of the record as a whole, the State Board of Pharmacy hereby adjudicates the
matter of Raymond P. Denuit as follows:
(A) On the basis, of the Findings of Fact and Conclusions of Law set forth above,
the State Board of Pharmacy hereby imposes a monetary penalty of two
thousand five hundred dollars ($2,500.00) on Raymond P. Denuit and
payment of the monetary penalty is due and owing within thirty days of the
mailing of this Order. The remittance should be made payable to the
"Treasurer, State of Ohio" and mailed with the enclosed form to the State
4 of 154
Board of Pharmacy, 77 South High Street, Room 1702, Columbus, Ohio

43215-6126.
(B) Further, Pursuant to Section 4729.16 of the Ohio Revised Code, and after
consideration of the record as a whole, the State Board of Pharmacy hereby
suspends indefinitely the pharmacist identification card, No. 03-1-10793, held
by Raymond P. Denuit and such suspension is effective as of the date of the
mailing of this Order.
(1) Raymond P. Denuit, pursuant to Rule 4729-9-01(F) of the Ohio

Administrative Code, may not be employed by or work in a facility
licensed by the State Board of Pharmacy to possess or distribute
dangerous drugs during such period of suspension.
(2) Raymond P. Denuit, pursuant to Section 4729.16(B) of the Ohio Revised

Code, must return his identification card and license (wall certificate) to
the office of the State Board of Pharmacy within ten days after receipt of
this Order unless the Board office is already in possession of both. The
identification card and wall certificate should be sent by certified mail,
return receipt requested.
Further, after two years from the effective date of this Order, the Board will
consider any petition filed by Raymond P. Denuit for a hearing, pursuant to Ohio
Revised Code Chapter 119., for reinstatement. The Board will only consider
reinstatement of the license to practice pharmacy in Ohio if the following
conditions have been met:
(A) Raymond P. Denuit must have submitted to the Board within 90 days from
this date of this Order a sexual offender-specific evaluation and follow all
recommendations thereof.
(B) Raymond P. Denuit must obtain sexual harassment in the workplace

sensitivity training and provide documentation to the Board of program
completion.
(C) Upon reappearance Raymond P. Denuit, must affirmatively show compliance

with his Board Order and overall fitness to practice pharmacy.
(D) Compliance with the continuing pharmacy education requirements set forth in
Chapter 4729-7 of the Ohio Administrative Code as applicable and in effect
on the date of petitioning the Board for reinstatement;
(E) If reinstatement is not accomplished within three years of the effective date of
this Order, Raymond P. Denuit must also show successful completion of the
North American Pharmacist Licensure Examination (NAPLEX) examination.
(F) Upon such time as the Board may consider reinstatement, Raymond P.
Denuit will be afforded a Chapter 119. hearing. At such time, the Board may
consider reinstatement with or without restrictions and/or conditions as the
Board deems appropriate under the circumstances.
Donald Casar moved for Findings of Fact; Deborah Lange seconded the motion.
Motion passed (Aye-6/Nay-0).
Gregory Braylock moved for Conclusions of Law; Jerome Wiesenhahn seconded

the motion. Motion passed (Aye-6/Nay-0).
5 of 154
Gregory Braylock moved for Action of the Board; Jerome Wiesenhahn seconded
the motion. Motion passed (Aye-6/Nay-0).
R-2009-278 After discussion, Mr. Braylock moved that the settlement offer in the matter of David Gary
Young, R.Ph. (03-1-09396) Bucyrus, Ohio, be denied. The motion was seconded by Ms.
Lange and approved by the Board: Aye – 5; Nay – 3.
R-2009-279 Mrs. Gregg moved that the Settlement Offer in the matter of Scott Wayne Savage, R.Ph. (03-
2-25203) Raleigh, North Carolina, be accepted. The motion was seconded by Ms. Pasquale
and approved by the Board: Aye – 8.
R-2009-280 Mrs. Gregg moved that the Settlement Offer in the matter of Charles E. Kelly, R.Ph. (03-1-
05746) Xenia, Ohio, be accepted. The motion was seconded by Mr. Casar and approved by the
Board: Aye – 8.
Mr. Keeley presented the Legislative Report.
R-2009-281 After discussion, Mr. Braylock moved that the amended rules listed below be approved and
filed in final form at the earliest effective date. Ms. Lange seconded the motion and it was
approved by the Board: Aye – 8.
Rule No. Rule Title

4729-
CHAPTER 4729-4 [QUALIFIED PHARMACY TECHNICIANS]
4-01 Definitions. (NEW)
4-03 Qualified pharmacy technician training program. (NEW)
4-04 Criminal records check for qualified pharmacy technicians. (NEW)
CHAPTER 4729-5 [PHARMACY PRACTICE]

5-36 Course requirements in the administration of immunizations.
5-37 Protocols for the administration of immunizations.
5-38 Immunization administration. (NEW)
CHAPTER-37 [DRUG DATABASE]

37-07 Frequency requirements for submitting drug database information.
6 of 154
FULL TEXT SHOWING CHANGES
UNDERLINED = Add New Language LINED THROUGH = Remove Old Language
4729-4-01 Definitions (Effective 6-21-09)
As used in Chapter 4729-4 of the Administrative Code:
(A) "Compounding" has the same meaning as defined in division (C) of section 4729.01 of the
Revised Code.
(B) "Package or label any drug" means the placement of a drug into a container or package and
the affixing of a drug label or drug information to the immediate drug container or drug
package.
(C) "Prepare or mix any intravenous drug to be injected into a human being" has the same
meaning as "Compounding" as defined in division (C) of section 4729.01 of the Revised Code.
(D) "Qualified pharmacy technician" has the same meaning as defined in section 4729.42 of the
Revised Code.
4729-4-03 Qualified pharmacy technician training program (Effective 6-21-09)
A pharmacy technician training program pursuant to division (E) of section 4729.42 of the Revised
Code shall be of appropriate breadth and depth, clearly addressing the competencies for a
technician to safely and effectively work in that particular setting and shall include at a minimum
the following:
(A) The applicable practice areas specified in division (B) of section 4729.42 of the Revised Code;
(B) Pharmacy terminology;
(C) Basic drug information;
(D) Basic calculations;
(E) Quality control procedures;
(F) State and federal laws, rules, and regulations regarding:
(1) Qualified pharmacy technician duties;
(2) Pharmacist duties;
(3) Pharmacy intern duties;

(4) Prescription or drug order processing procedures;
(5) Drug record keeping requirements;
(6) Patient confidentiality;
(7) Security requirements;
(8) Storage requirements.

7 of 154
4729-4-04 Criminal records check for qualified pharmacy technicians (Effective 6-21-09)
(A) Pursuant to sections 4729.42 and 4776.02 of the Revised Code, the criminal records check
performed by the Ohio bureau of criminal identification and investigation (BCI&I) shall consist
of both a BCI&I criminal records check and a federal bureau of investigation (FBI) criminal
records check. BCI&I shall send the results of the BCI&I criminal records check directly to the
employer or potential employer. BCI&I shall provide a letter regarding the FBI criminal
records check to the employer or potential employer stating that there is either no record of
any conviction or a letter stating that the request may not meet the criteria. When an
employer or potential employer receives a letter stating that the request may not meet the
criteria, they may share this information with the employee or potential employee. In order
to complete the criminal records check, the employee or potential employee must then
complete a “Request for Release-FBI Rapsheet” and send it to BCI&I to request a copy of the
FBI criminal record results be sent directly to the employee or potential employee. The
employee or potential employee is then responsible for providing the FBI criminal records
check results to the employer or potential employer. The employee or potential employee
must provide the results to the employer or potential employer in the original sealed envelope
received from BCI&I.
(B) The criminal records check shall be based on electronic fingerprint impressions that are
submitted directly to BCI&I from a “WebCheck” provider agency located in Ohio. The
employer may accept the results of a criminal records check based on ink impressions from a
“WebCheck” provider agency only in the event that readable electronic fingerprint impressions
cannot be obtained.
4729-5-36 Course requirements in the administration of immunizations (Effective 6-21-09)
(A) A course in the administration of immunizations developed pursuant to division (B)(1) of

section 4729.41 of the Revised Code shall meet at least the following requirements:
(1) The instructor shall be a licensed health care professional and have the appropriate
education and experience to teach a course in the administration of immunizations.
(2) The content must meet the standards established for such courses by the centers for
disease control and prevention in the public health service of the United States
department of health and human services.
(3) The course must be a minimum of five hours in length and include at least the following:
(a) A review of immunology that includes a discussion of the body's immune system
reaction to the immunizations.
(b) A review of each medication listed in division (A) of section 4729.41 of the Revised
Code and in rule 4729-5-38 of the Administrative Code that includes the following:
(i) Disease states associated with the immunization;
(ii) Type or nature of activity of the immunization;
(iii) Appropriate administration schedules;
(iv) Appropriate routes of administration;

8 of 154
(v) Appropriate injection sites;
(vi) Appropriate dosages;
(vii) Appropriate monitoring and treatment of the patient for adverse reactions;
(viii) Appropriate patient populations;
(ix) Precautions and contraindications;
(x) Proper storage requirements for the immunization.
(c) A review of sterile technique in injectable dosage preparation and administration.
(d) A minimum of one hour of instruction and physical participation in administration

techniques.
(e) A review of the proper disposal procedures for contaminated needles and
immunizations.
(f) A review of the proper procedures for accidental needle sticks.
(4) The course must provide a method to evaluate the successful mastery of the content.
(B) All courses in immunizations must be submitted to the state board of pharmacy for approval.
The courses may be reviewed with the state medical board and the board of nursing, as
appropriate. Any subsequent revisions to the course, after the initial approval, must be
submitted to the state board of pharmacy for approval.
4729-5-37 Protocols for the administration of immunizations (Effective 6-21-09)
(A) To be considered an approved protocol pursuant to division (B)(3) of section 4729.41 of the
Revised Code, the physician-established protocol for the administration of immunizations
must include at least the following:
(1) For each medication listed in division (A) of section 4729.41 of the Revised Code and in
rule 4729-5-38 of the Administrative Code:
(a) Name and strength;
(b) Precautions and contraindications;
(c) Intended audience or patient population;
(d) Appropriate dosage;
(e) Appropriate administration schedules;

(f) Appropriate routes of administration;
(g) Appropriate injection sites;
(2) The length of time the pharmacist or pharmacy intern under the direct supervision of a
pharmacist must observe an individual for adverse effects, which shall be based on
appropriate standards of care established by the physician. The location of the
observation shall be in the general vicinity of the administering pharmacist or pharmacy
intern to allow for on-going evaluation.
9 of 154
(3) A method to address emergency situations including, but not limited to, adverse
reactions, anaphylactic reactions, and accidental needle sticks.
(4) A method to notify an individual's physician or the applicable board of health within
thirty days after administering medication, except for influenza immunizations
administered to individuals eighteen years of age and older.
(5) The locations that a pharmacist or pharmacy intern under the direct supervision of a
pharmacist may engage in the administration of immunizations.
(B) All physician-established protocols must be signed and dated by the physician prior to
implementation and maintained by the administering pharmacist. The pharmacist must renew
the protocol annually with the physician.
(C) Upon the request of the state board of pharmacy, a pharmacist shall immediately provide the
protocols for immunizations pursuant to division (B)(3) of section 4729.41 of the Revised
Code. The state board of pharmacy, after review, may approve the protocol or return it to the
pharmacist for revision without approval. If a protocol has been returned for revision without
approval, it may not be implemented until the board has approved it. The state board of
pharmacy may review the protocols with the state medical board and the board of nursing, as
appropriate.
4729-5-38 Immunization administration (Effective 6-21-09)
In addition to the immunizations and medications listed in section 4729.41 of the Revised Code and
pursuant to the requirements noted in section 4729.41 of the Revised Code and rules 4729-5-36
and 4729-5-37 of the Administrative Code, a pharmacist may administer the zoster vaccine
according to the following requirements:
(A) The pharmacist must receive a patient specific prescription prior to administration of the
drug;
(B) The vaccine must be administered within thirty days of the issuance of the prescription;
(C) The patient must meet the age criteria specified in the F.D.A. approved labeling; and
(D) The pharmacist must be able to document meeting the training criteria required by rule 4729-
5-36.
4729-37-07 Frequency requirements for submitting drug database information

(Effective 6-21-09)
(A) All Until August 31, 2009, all drug dispensing information required to be submitted to the
board of pharmacy pursuant to rules 4729-37-02 and 4729-37-04 of the Administrative Code
must be submitted twice a month as follows:
(1) During the first through the fifth day of each month; and
(2) During the fifteenth through the twentieth day of each month; and
10 of 154
(3) The information shall be consecutive and inclusive from the last date and time
information was submitted and shall be reported no later than twenty-one days after the
date of the dispensing.
(B) Starting on September 1, 2009, all drug dispensing information required to be submitted to
the board of pharmacy pursuant to rules 4729-37-02 and 4729-37-04 of the Administrative
Code shall be submitted at least weekly. The information shall be consecutive and inclusive
from the last date and time information was submitted and shall be reported no later than
eight days after the date of the dispensing.
(C) If a pharmacy has no drug dispensing information required to be submitted to the board of
pharmacy pursuant to rules 4729-37-02 and 4729-37-04 of the Administrative Code, the
pharmacy shall submit a "Zero Report" during the regular reporting cycle.
(B)(D) All wholesale drug sale information required to be submitted to the board of pharmacy
pursuant to rules 4729-37-02 and 4729-37-04 of the Administrative Code must be submitted
monthly as follows:
(1) During the first through the tenth day of each month; and
(2) The information shall be consecutive and inclusive from the last date and time
information was submitted and shall be reported no later than forty days after the date
of the wholesale sale.
(C)(E) In the event that a wholesaler or pharmacy cannot submit the required information as
described in this rule they must immediately contact the board of pharmacy to determine a
mutually acceptable time for submission of information. The wholesaler or pharmacy must
document in writing to the board of pharmacy the reasons for their inability to submit the
required information.
R-2009-282 After discussion, Mr. Braylock moved that rule 4729-4-02 be refiled as amended by the Board.
Ms. Lange seconded the motion and it was approved by the Board: Aye – 8.
Ms. Lange reported that the Medical Board Physician Assistant Policy Committee has met
since the last Pharmacy Board meeting and further reports will be given at the July meeting.
3:34 p.m. Mr. Wiesenhahn left the meeting temporarily for personal reasons.
R-2009-283 Mr. Keeley presented the Ohio Pharmacists Association Herpes Zoster Vaccine Immunization
course. Mr. Braylock moved that the program be approved and the motion was seconded by
Mr. Casar. It was approved by the Board: Aye – 7.
3:37 p.m. Mr. Wiesenhahn rejoined the meeting in progress.
R-2009-284 The Board considered a request for an exemption to Ohio Administrative Code Rule 4729-5-10
(Prescription pick-up station) received for the following sites:
HM Home Pharmacy, Girard, Ohio (02-0945950)

Youngstown Neurological Center, Youngstown, Ohio (02-1690000)
St Elizabeth Health Center, Youngstown, Ohio (02-0915250)
St Elizabeth Boardman Health Center, Boardman, Ohio (02-1237950)
St. Joseph Health Center, Warren, Ohio (02-0903950)
St. Joseph Pain Clinic, Warren, Ohio (02-1723000)
11 of 154
After discussion, Mrs. Gregg moved that the Board approve the request as long as the parties
to the request comply with the requirements in the rule for such an exemption. The motion was
seconded by Mr. Casar and approved by the Board: Aye – 8.
R-2009-285 The Board considered a request for an exemption to Ohio Administrative Code Rule 4729-5-10
(Prescription pick-up station) received for the following sites:
KHN Pharmacy - Sycamore, Miamisburg, Ohio (02-1076650)

Greene Memorial Hospital Pharmacy, Xenia, Ohio (02-0031250)
After discussion, Mr. Wiesenhahn moved that the Board approve the request as long as the
parties to the request comply with the requirements in the rule for such an exemption. The
motion was seconded by Ms. Pasquale and approved by the Board: Aye – 8.
R-2009-286 Mr. Braylock moved that the Board elect Mrs. Gregg to serve as Board President for FY 2010.
The motion was seconded by Mr. Casar and approved by the Board: Aye – 8.
R-2009-287 Mrs. Gregg moved that the Board elect Ms. Pasquale to serve as Vice-President for FY 2010.
Ms. Lange seconded the motion and approved by the Board: Aye – 8.
4:21 p.m. The Board recessed for the day.
Tuesday, June 9, 2009
8:45 a.m. The Board reconvened with the following members present:
Nathan S. Lipsyc, R.Ph., President; Elizabeth I. Gregg, R.Ph., Vice-President; Gregory

Braylock, R.Ph.; Donald M. Casar, R.Ph.; Richard F. Kolezynski, R.Ph.; Deborah A. Lange,
R.Ph.; Heather L. Pasquale, R.Ph.; and Jerome J. Wiesenhahn, R.Ph.
9:00 a.m. The Board was joined by Assistant Attorney General Tracy Marie Greuel to conduct an
adjudication hearing in accordance with the Ohio Revised Code Chapters 119. and 4729. in the
matter of Gary A. Holschuh, R.Ph. (03-1-22847) Willow Wood, Ohio.
9:46 a.m. Mrs. Gregg moved that the Board go into Executive Session for the purpose of the investigation
Revised Code. The motion was seconded by Ms. Pasquale and a roll-call vote was conducted
by President Lipsyc as follows: Braylock – yes; Casar – yes; Gregg – yes; Kolezynski – yes;
Lange – yes; Pasquale – yes; and Wiesenhahn – yes.
10:05 a.m. The Executive Session ended and the hearing in the matter of Gary Holschuh resumed.
10:06 a.m. The hearing was continued to a future date.
The Board recessed briefly.
10:18 a.m.
R-2009-288 After discussion, Mrs. Gregg moved that the Board minutes of May 4– 7, 2009, be approved as
amended. Ms. Lange seconded the motion and it was approved by the Board: Aye – 7.
R-2009-289 After discussion, Mrs. Gregg moved that the Conference Call minutes of May 22, 2009, be
approved as amended. Mr. Casar seconded the motion and it was approved by the Board: Aye
– 7.
12 of 154
R-2009-290 After discussion, Mrs. Gregg moved that the Conference Call minutes of June 3, 2009, be
approved as amended. Mr. Casar seconded the motion and it was approved by the Board: Aye
– 7.
Mr. Braylock reported on the May 11, 2009, meeting of the Nursing Board Committee on
Prescriptive Governance.
11:20 a.m. The Board recessed briefly.
11:34 a.m. The Board met with Kevin Fearon and Joe Sabino regarding the Millennium Pharmacy
Systems request.
12:24 p.m. The meeting with the Millennium Pharmacy Systems representatives ended.
12:25 p.m. The Board recessed for lunch.
1:30 p.m.
R-2009-291 The following candidates for licensure by reciprocity met with the following members of the
Board in Room South A, 31st Floor of the Vern Riffe Center.
Nathan S. Lipsyc, R.Ph., President; Elizabeth I. Gregg, R.Ph., Vice-President; Gregory

Braylock, R.Ph.; Donald M. Casar, R.Ph.; Richard F. Kolezynski, R.Ph.; Deborah A. Lange,
R.Ph.; Heather L. Pasquale, R.Ph.; and Jerome J. Wiesenhahn, R.Ph.
The candidates introduced themselves to the Board, and then participated in a discussion of
pharmacy laws and rules with Joann Predina, Compliance Specialist.
Natalie Trinh Eckman Virginia

Daniel Luke Graber Texas
Maria Rose Guido Michigan
Hester Hommel Oklahoma
Nkechi Lilian Iwuanyanwu New Jersey
Albert K. Lau California
Sara Soliman Matta Pennsylvania
Hetal Mukesh Patel Michigan
Nirali Patel Pennsylvania
Adriana Pereira Arizona
Kirk Brian Price North Carolina
Debbie Lynn Robinson Michigan
Linda Marie Rocchi Pennsylvania
Amarsena R. Sappidi Michigan
James Keith Smith Michigan
Brian Keith Yarde Illinois
Margaret Ann Kittle Pennsylvania
Min Kong Florida
Andrea Nigg Michigan
Jaydeep M. Rana New Jersey
Dina R. Patel Michigan
2:03 p.m. The Board reconvened in Room East B, 31st Floor, of the Vern Riffe Center for Government and
the Arts and was joined by Assistant Attorney General Tracy Marie Greuel to conduct an
matter of Christy T. Stricker, R.Ph. (03-3-11706) Granville, Ohio.
5:26 p.m. The hearing ended and the record was closed.
13 of 154
5:28 p.m. Mrs. Gregg moved that the Board go into Executive Session for the purpose of the investigation
Revised Code. The motion was seconded by Mr. Casar and a roll-call vote was conducted by
President Lipsyc as follows: Braylock – yes; Casar – yes; Gregg – yes; Kolezynski – yes; Lange
– yes; Pasquale – yes; and Wiesenhahn – yes.
5:38 p.m. The Executive Session ended and the meeting was opened to the public.
R-2009-292 After votes were taken in public session, the Board adopted the following order in the matter of
Christy T. Stricker, R.Ph. (03-3-11706) Granville, Ohio.

in the matter of:
CHRISTY T. STRICKER, R.Ph.

76 Falmouth Road, S.E.
Granville, Ohio 43023
R.Ph. Number 03-3-11706
INTRODUCTION
The matter of Christy T. Stricker came for hearing on June 9, 2009, before the following members
of the Board: Nathan S. Lipsyc, R.Ph. (presiding); Gregory Braylock, R.Ph.; Donald M. Casar,
R.Ph.; Elizabeth I. Gregg, R.Ph.; Richard F. Kolezynski, R.Ph.; Deborah A. Lange, R.Ph.;
Heather L. Pasquale, R.Ph.; and Jerome J. Wiesenhahn, R.Ph.
Barton G. Kaderly, Public Member; absent.
Christy T. Stricker was represented by Daniel D. Connor. The State of Ohio was represented by
Tracy Marie Greuel, Assistant Attorney General.
SUMMARY OF EVIDENCE
State’s Witnesses: Kevin Joseph Kinneer, Ohio State Board of Pharmacy

Betty Jones, R.Ph., Ohio State Board of Pharmacy
Christy T. Stricker, R.Ph., Repondent
Respondent's Witness: Christy T. Stricker, R.Ph., Respondent
State's Exhibits:
1. Letter of Representation from Daniel D. Connor, Esq. [09-04-08]
1A. Copy of Summary Suspension Order/Notice of Opportunity For Hearing letter [09-10-08]
1B-1E. Procedurals
2. Notarized Statement of Christy T. Stricker [08-26-08]
2A. Notarized Statement of Heather Howe [08-27-08]
2B. Notarized Statement of Sharon Hull, RN, BSN [10-08-08]
3. Kroger Pharmacy N844, DVD Recording of Dates [07-25-08 and 07-29-08]
4. Dangerous Drug Distributor Inspection Report [08-26-08]
5. Perpetual Controlled Substance Inventory Record for Provigil 100 mg [05-01-08 to 08-16-08]
5A. Perpetual Controlled Substance Inventory Record for alprazolam 1 mg [06-24-08 to 08-20-
08]
5B. Perpetual Controlled Substance Inventory Record for Diazepam 10 mg Tabs [02-26-08 to
08-20-08]
14 of 154
5C. Perpetual Controlled Substance Inventory Record for hydrocodone/APAP 10/325 mg [02-20-
08 to 08-20-08]
5D. Notarized Statement of Colleen Childress [08-22-08]
6. Evidence box of items taken from Christy Stricker on 08-25-08
6A. Shoes-size 6.5 black and white "Basic Edition"
6B. Red and black bag
6C. Small bag with photo, white and red, #30 tabs - white M357
6D. Unmarked prescription vial of #2 hydrocodone 5/500, #73 tramadol 50 mg, #34 alprazolam 1
mg, and #11 Provigil 200 mg
6E. Unmarked prescription vial of #2 tramadol and #1 loratadine
6F. Unmarked prescription vial with #1 cap Pfizer PGN 100 and bottle marked "Excedrin Etc."
with Excedrin TH tablets
6G. Two boxes of Zomig 2.5 mg with 6 tabs in each box
6H. 10 tabs Zofran ODT 4 mg; 5 tabs Relpax 40 mg; other miscellaneous drugs
6 I. One plastic bottle, blue and clear, empty; 1 plastic bottle, blue and clear, with #87 tramadol,
#23 Provigil 200 mg, and #1 hydrocodone 5/500
6J. One alprazolam 1 mg
6K. Plastic bag containing 2 boxes of Benicar 20 mg with 7 tabs per box, 4 boxes of Plavix 75 mg
with 4 tabs per box, 4 boxes of Actonel 150 mg with 1 tab per box, 2 sleeves of Crestor 20
mg with 7 tabs per box, 9 packets of Cozaar 100 mg with 7 tabs per box, 1 box of Avandia 8
mg with 7 tabs per box, 1 box of Actos 30 mg with 7 tabs per box, and 1 box of Lantus insulin
A. PRO Pharmacist's Recovery Contract for Christy Stricker [03-27-09]
B. Treatment Letter from Marjorie A. Stein of Licking County Alcoholism Prevention Program
[01-20-09]; Treatment Information Letter and Status Report from Marjorie A. Stein to Daniel
Conner (sic) [05-11-09]
C. Questhouse Inc. Treatment and Discharge Records for Christy T. Stricker [01-23-09 to 02-
20-09]
D. Questhouse Urine Drug Screen Reports [01-23-09 to 02-20-09]
E. First Lab OHPRO Test History Reports [04-23-09 and 05-22-09]; Drug Screen Panel [06-11-
06]
F. Support Group Attendance Records [09-16-08 to 06-06-09]
G. Ten Letters of Support [05-08-09 to 06-07-09]
FINDINGS OF FACT
After having heard the testimony, observed the demeanor of the witnesses, considered the
evidence, and weighed the credibility of each, the State Board of Pharmacy finds the following to
be fact:
(1) Records of the Board of Pharmacy indicate that Christy T. Stricker was originally licensed in
the State of Ohio on August 4, 1976, pursuant to examination, and her license to practice
pharmacy in Ohio was Summarily Suspended effective September 10, 2008.
(2) Christy T. Stricker is addicted to or abusing drugs and/or impaired physically or mentally to
such a degree as to render her unfit to practice pharmacy, to wit: Christy T. Stricker has
admitted to being addicted to tramadol, a dangerous drug; Christy T. Stricker has admitted to
stealing dangerous drugs and controlled substances from her various employers; Christy T.
Stricker has admitted to stealing and then giving drugs to others for self-treatment purposes;
Christy T. Stricker was observed by the hospital's director of nursing while she was practicing
pharmacy to be acting in a manner considered to be "bizarre" to such an extent that she felt
Christy T. Stricker needed monitored. Such conduct indicates that Christy T. Stricker is
within the ambit of Sections 3719.121(B) and/or 4729.16(A)(3) of the Ohio Revised Code.
(3) Christy T. Stricker did, on or about July 29, 2008, with purpose to deprive, knowingly obtain
or exert control over dangerous drugs, the property of Kroger Pharmacy N-844, beyond the
15 of 154
express or implied consent of the owner, to wit: Christy T. Stricker was observed, and
admitted to, stealing 200 tablets of hydrocodone 7.5 mg with ibuprofen 200 mg, a Schedule
III controlled substance. Such conduct is in violation of Section 2913.02 of the Ohio Revised
Code.
(4) Christy T. Stricker did, on or about August 25, 2008, knowingly possess a controlled
substance when the conduct was not in accordance with Chapters 3719., 4729., and 4731. of
the Ohio Revised Code, to wit: Christy T. Stricker possessed the following drugs that she had
stolen from her employers without a prescription from an authorized prescriber and not for a
legitimate medical purpose:
Drug Quantity Schedule

Provigil 200 mg 34 IV
hydrocodone 5mg w/acetaminophen 500 mg 32 III
alprazolam 1 mg 34 IV
Such conduct is in violation of Section 2925.11 of the Ohio Revised Code.
(5) Christy T. Stricker did, on or about August 25, 2008, possess a dangerous drug when not in
accordance with Chapters 4729. and 4731. of the Ohio Revised Code, to wit: Christy T.
Stricker possessed the following drugs that she had stolen from her employers without a
prescription from an authorized prescriber and not for a legitimate medical purpose:
Drug Quantity Schedule

Zomig 2.5mg 12 dd
Replax 5 dd
tramadol 50mg 163 dd
Such conduct is in violation of Section 4729.51(C)(3) of the Ohio Revised Code.
(6) Christy T. Stricker did, on or about August 25, 2008, possess for sale at retail a dangerous
drug when not in accordance with Chapters 4729. and 4731. of the Ohio Revised Code, to
wit: Christy T. Stricker possessed 10 tablets of Zofran ODT 4 mg that she had stolen from her
employer and without a prescription from an authorized prescriber and not for a legitimate
medical purpose. Christy T. Stricker admittedly intended to sell (give) the drugs to another for
her use. Such conduct is in violation of Section 4729.51(C)(2) of the Ohio Revised Code.
(7) Christy T. Stricker did, on or about August 8 through August 10, 2008, with purpose to
deprive, knowingly obtain or exert control over dangerous drugs, the property of Regency
Hospital of Cincinnati, beyond the express or implied consent of the owner, to wit: Christy T.
Stricker admittedly stole Provigil 100 mg, hydrocodone 10 mg w/acetaminophen 325 mg, and
diazepam 10 mg for her own personal abuse, and alprazolam 1 mg for another’s use. Such
conduct is in violation of Section 2913.02 of the Ohio Revised Code.
CONCLUSIONS OF LAW
(1) The State Board of Pharmacy concludes that paragraphs (3) through (7) of the Findings of
Fact constitute being guilty of gross immorality as provided in Division (A)(1) of Section
Fact constitute being guilty of dishonesty and unprofessional conduct in the practice of
pharmacy as provided in Division (A)(2) of Section 4729.16 of the Ohio Revised Code.
(3) The State Board of Pharmacy concludes that paragraph (2) of the Findings of Fact
constitutes being addicted to or abusing liquor or drugs or impaired physically or mentally to
16 of 154
such a degree as to render her unfit to practice pharmacy as provided in Division (A)(3) of
Section 4729.16 of the Ohio Revised Code.
Fact constitute being guilty of willfully violating, conspiring to violate, attempting to violate, or
aiding and abetting the violation of provisions of Chapter 2925.of the Revised Code as
provided in Division (A)(5) of Section 4729.16 of the Ohio Revised Code.
Pursuant to Section 3719.121 of the Ohio Revised Code, the State Board of Pharmacy hereby
removes the Summary Suspension Order issued to Christy T. Stricker on September 10, 2008.
Pursuant to Section 4729.16 of the Ohio Revised Code, and after consideration of the record as a
whole, the State Board of Pharmacy hereby suspends indefinitely the pharmacist identification
card, No. 03-3-11706, held by Christy T. Stricker and such suspension is effective as of the date
of the mailing of this Order.
(A) Christy T. Stricker, pursuant to Rule 4729-9-01(F) of the Ohio Administrative Code, may not
be employed by or work in a facility licensed by the State Board of Pharmacy to possess or
distribute dangerous drugs during such period of suspension.
(B) Christy T. Stricker, pursuant to Section 4729.16(B) of the Ohio Revised Code, must return
her identification card and license (wall certificate) to the office of the State Board of
Pharmacy within ten days after receipt of this Order unless the Board office is already in
possession of both. The identification card and wall certificate should be sent by certified
mail, return receipt requested.
Further, after two years from the effective date of this Order, the Board will consider any petition
filed by Christy T. Stricker for a hearing, pursuant to Ohio Revised Code Chapter 119., for
reinstatement. The Board will only consider reinstatement of the license to practice pharmacy in
Ohio if the following conditions have been met:
(A) Christy T. Stricker must continue following the advice of a licensed psychiatrist or
psychologist.
(B) Christy T. Stricker must enter into a new contract, signed within thirty days after the effective
date of this Order, with an Ohio Department of Alcohol and Drug Addiction Services
(ODADAS) treatment provider or a treatment provider acceptable to the Board for a period of
not less than five years and, upon signing, submit a copy of the contract to the Board office.
The contract must provide that:
(1) Random, observed urine drug screens shall be conducted at least once each month.
(a) The urine sample must be given within twelve hours of notification. The urine drug
screen must include testing for creatinine or specific gravity of the sample as the
dilutional standard.
(b) Results of all drug screens must be negative. Refusal of a drug screen or a diluted
drug screen is equivalent to a positive result. Any positive results, including those
which may have resulted from ingestion of food, but excluding false positives which
resulted from medication legitimately prescribed, indicates a violation of the contract.
(2) Attendance is required a minimum of three times per calendar week at an Alcoholics
Anonymous, Narcotics Anonymous, and/or similar support group meeting.
17 of 154
(3) The program shall immediately report to the Board any violations of the contract and/or
lack of cooperation.
(C) Christy T. Stricker must demonstrate satisfactory proof to the Board that she is no longer
addicted to or abusing drugs or impaired physically or mentally to such a degree as to render
her unfit to practice pharmacy.
(D) Christy T. Stricker must provide, at the reinstatement petition hearing, documentation of the
following:
(1) Compliance with the licensed psychiatrist's or psychologist's recommended treatment

plan.
(2) A report by the licensed psychiatrist or psychologist regarding Christy Stricker's fitness for
readmission into the practice of pharmacy.
(3) Compliance with the contract required above (e.g. proof of giving the urine sample within
twelve hours of notification, copies of all urine screen reports, meeting attendance
records, treatment program reports, etc.).
(4) Compliance with the continuing pharmacy education requirements as set forth in Chapter
4729-7 of the Ohio Administrative Code.
(5) Compliance with the terms of this Order.
(6) Fitness to re-enter the practice of pharmacy.
(E) If reinstatement is not accomplished within three years of the effective date of this Order,
Christy T. Stricker must show successful completion of the North American Pharmacist
Licensure Examination (NAPLEX) or an equivalent examination approved by the Board.
Jerome J. Wiesenhahn moved for Findings of Fact; Donald M. Casar seconded the motion.
Elizabeth I. Gregg moved for Conclusions of Law; Heather L. Pasquale seconded the motion.
Donald M. Casar moved for Action of the Board; Deborah A. Lange seconded the motion. Motion
passed (Aye-7/Nay-0).
5:41 p.m. The Board recessed for the day.
Wednesday, June 10, 2009
7:50 a.m. The Board reconvened in room East B, 31st Floor, of the Vern Riffe Center for Government and
the Arts, 77 South High Street, Columbus, Ohio, with all members present.
8:10 a.m. The adjudication hearing from May 5, 2009, in the matter of Jonathan Price Shelton, R.Ph. (03-
3-11927) Dayton, Ohio, resumed.
12:16 p.m. The Board recessed for lunch.
1:22 p.m. The adjudication hearing in the matter of Jonathan Price Shelton resumed.
18 of 154
Mrs. Gregg moved that the Board go into Executive Session for the purpose of the investigation
Revised Code. The motion was seconded by Mr. Kaderly and a roll-call vote was conducted by
President Lipsyc as follows: Braylock – yes; Casar – yes; Gregg – yes; Kaderly – yes; Kolezynski
– yes; Lange – yes; Pasquale – yes; and Wiesenhahn – yes.
3:10 p.m.
Jonathan Price Shelton, R.Ph. (03-3-11927) Dayton, Ohio.

in the matter of:
JONATHAN PRICE SHELTON, R.Ph.

1613 Far Hills Avenue
Dayton, Ohio 45419
R.Ph. Number 03-3-11927
INTRODUCTION
The matter of Jonathan Price Shelton came for hearing on May 5, 2009 and June 10,
2009, before the following members of the Board: Nathan S. Lipsyc, R.Ph. (presiding);
Gregory Braylock, R.Ph.; Donald M. Casar, R.Ph.; Elizabeth I. Gregg, R.Ph.; Barton G.
Kaderly, Public Member; Richard F. Kolezynski, R.Ph.; Deborah A. Lange, R.Ph.;
Heather L. Pasquale, R.Ph.; and Jerome J. Wiesenhahn, R.Ph.
Jonathan Price Shelton was represented by James T. Ambrose. The State of Ohio was
represented by Tracy Marie Greuel, Assistant Attorney General.
SUMMARY OF EVIDENCE
State’s Witnesses: Jesse Wimberly, Ohio State Board of Pharmacy

Jonathan Price Shelton, R.Ph., Respondent
Respondent's Witness: Jonathan Price Shelton, R.Ph., Respondent
State's Exhibits:
1. Copy of Notice of Opportunity For Hearing letter [03-13-09]
1A-1F. Procedurals
2. Pictures from Shelton Pharmacy
3. DVD of Dispensing Map [not dated]
3A. Map of Prescriptions Dispensed by State [not dated]
3B. Samples of Prescriptions Used for Dispensing [01-09-07 to 09-12-07]
3C. Entire File of Scanned Prescriptions
4. Notarized Statement of Jonathan P. Shelton [10-10-07]
5. Drug Price List from Jonathan Shelton [10-10-07]
6. Ohio State Board of Pharmacy News, www.pharmacy.ohio.gov [February 2007]
7. AlphaNet-trading.com website printout [10-08-07]
8. Notarized Statement of William K. Smith, Jr., DPM with copies of prescriptions [08-
28-08]
9. RX Partners internet website solicitation [08-28-08]
10. Notarized Statement of Anthony Rattini with attachments [10-02-08]
11. Dangerous Drug Certification [01-28-09]
19 of 154
12. Key Bank Transaction Report [01-09-09]

13: Notarized Statement of Anthony Rattini [05-28-09]
14. Box containing 7,191 internet prescriptions filled by Respondent at Shelton
Pharmacy [01-11-07 to 09-13-07]
A. Key Bank Checking Account Details Report [01-01-07 to 09-15-07]
B. Ohio State Board of Pharmacy Testimony Before the Committee on the Judiciary,
Subcommittee on Crime, Terrorism, and Homeland Security [06-24-08]
C. Decision and Entry Finding the Defendant Not Guilty After Trial to The Court, State of
Ohio vs. Jonathan Shelton, Case No. 08-CR-1559, Montgomery County Common
Pleas Court [02-06-09]
FINDINGS OF FACT
After having heard the testimony, observed the demeanor of the witnesses, considered
the evidence, and weighed the credibility of each, the State Board of Pharmacy finds the
following to be fact:
(1) Records of the State Board of Pharmacy indicate that Jonathan Price Shelton was
originally licensed in the State of Ohio on August 4, 1976, pursuant to examination,
and is currently licensed to practice pharmacy in the State of Ohio.
(2) Jonathan Price Shelton did, from January 10, 2007, through September 12, 2007,
sell a dangerous drug when the conduct was not in accordance with Chapters 4729.
and 4731. of the Ohio Revised Code, to wit: Jonathan Price Shelton admittedly sold
the following prescriptions pursuant to internet sales without a valid physician-patient
relationship:
Qty Pt. Pres.

Date Filled Script# Drug Strength Disp. State State R.Ph.
08-15-2007 793807 acyclovir 200 mg 90 IN CA JS
09-10-2007 5113029 acyclovir 200 mg 30 NY CA JS
Such conduct is in violation of Section 4729.51(C) of the Ohio Revised Code.
(3) Jonathan Price Shelton did, from January 10, 2007, through September 12, 2007,
sell a dangerous drug when the conduct was not in accordance with Chapters 4729.
and 4731. of the Ohio Revised Code, to wit: Jonathan Price Shelton admittedly sold
the following prescriptions pursuant to internet sales without a valid physician-patient
relationship:
Qty Pt. Pres.

05-02-2007 760741 acyclovir 400 mg 90 CT CA JS
06-13-2007 773316 acyclovir 400 mg 90 CA CA JS
06-19-2007 775108 acyclovir 400 mg 90 TX CA JS
09-06-2007 5111847 acyclovir 400 mg 90 CA OK JS
(4) Jonathan Price Shelton did, from January 10, 2007, through September 12, 2007, sell a
dangerous drug when the conduct was not in accordance with Chapters 4729. and 4731. of the
Ohio Revised Code, to wit: Jonathan Price Shelton admittedly sold the following prescriptions
pursuant to internet sales without a valid physician-patient relationship:
20 of 154
Qty Pt. Pres.

08-06-2007 790666 acyclovir 800 mg 90 WA CA JS
08-14-2007 793781 acyclovir 800 mg 90 MO CA JS
08-29-2007 5105755 acyclovir 800 mg 90 OR OK JS
09-12-2007 5115254 acyclovir 800 mg 90 CA OK JS
Qty Pt. Pres.

06-27-2007 777792 amoxicillin 250 mg 30 UT CA JS
07-19-2007 785274 amoxicillin 250 mg 30 VA CA JS
07-31-2007 788957 amoxicillin 250 mg 30 CA CA JS
Qty Pt. Pres.

05-04-2007 761409 amoxicillin 500 mg 30 UT CA JS
05-09-2007 762783 amoxicillin 500 mg 30 AZ CA JS
05-14-2007 764004 amoxicillin 500 mg 30 NJ CA JS
07-02-2007 779266 amoxicillin 500 mg 30 IN CA JS
07-05-2007 780502 amoxicillin 500 mg 30 MD CA JS
07-19-2007 785202 amoxicillin 500 mg 30 TX CA JS
07-24-2007 786637 amoxicillin 500 mg 30 OH CA JS
08-13-2007 792426 amoxicillin 500 mg 30 MA CA JS
08-23-2007 4003059 amoxicillin 500 mg 30 TX CA JS
08-23-2007 4003074 amoxicillin 500 mg 30 MA CA JS
08-23-2007 4003137 amoxicillin 500 mg 30 ID CA JS
08-31-2007 5108076 amoxicillin 500 mg 30 CO CA JS
09-07-2007 5112377 amoxicillin 500 mg 30 GA CA JS
dangerous drug when the conduct was not in accordance with Chapters 4729. and 4731. of
the Ohio Revised Code, to wit: Jonathan Price Shelton admittedly sold the following
prescriptions pursuant to internet sales without a valid physician-patient relationship:
21 of 154
Qty Pt. Pres.

07-18-2007 783583 Atarax 50 mg 30 PA CA JS
08-09-2007 791964 Atarax 50 mg 90 PA CA JS
08-31-2007 5107999 Atarax 50 mg 90 NJ OK JS
09-04-2007 5108546 Atarax 50 mg 60 LA OK JS
09-04-2007 5108668 Atarax 50 mg 30 TN OK JS
09-12-2007 5115365 Atarax 50 mg 30 GA OK JS
the Ohio Revised Code, to wit: Jonathan Price Shelton admittedly sold the following
Qty Pt. Pres.

01-11-2007 730579 butalbital/APAP/caffeine 50/325/40 mg 90 OH CA 1234
01-11-2007 730588 butalbital/APAP/caffeine 50/325/40 mg 90 CA CA 1234
01-11-2007 730599 butalbital/APAP/caffeine 50/325/40 mg 90 GA CA 1234
01-12-2007 727094 butalbital/APAP/caffeine 50/325/40 mg 90 VA CA JS
01-12-2007 728578 butalbital/APAP/caffeine 50/325/40 mg 90 TX CA JS
01-15-2007 731027 butalbital/APAP/caffeine 50/325/40 mg 90 PA CA JS
01-15-2007 731035 butalbital/APAP/caffeine 50/325/40 mg 90 CA CA JS
01-15-2007 731081 butalbital/APAP/caffeine 50/325/40 mg 90 NY CA JS
01-16-2007 730873 butalbital/APAP/caffeine 50/325/40 mg 90 CT CA JS
01-16-2007 730953 butalbital/APAP/caffeine 50/325/40 mg 90 NH CA JS
01-16-2007 731019 butalbital/APAP/caffeine 50/325/40 mg 90 OH CA JS
01-18-2007 728728 butalbital/APAP/caffeine 50/325/40 mg 90 GA CA JS
01-18-2007 729989 butalbital/APAP/caffeine 50/325/40 mg 90 MD CA JS
01-18-2007 731878 butalbital/APAP/caffeine 50/325/40 mg 90 AR CA JS
01-18-2007 731897 butalbital/APAP/caffeine 50/325/40 mg 90 AL CA JS
01-19-2007 732261 butalbital/APAP/caffeine 50/325/40 mg 60 WY CA JS
01-22-2007 732680 butalbital/APAP/caffeine 50/325/40 mg 90 CO CA JS
01-22-2007 732701 butalbital/APAP/caffeine 50/325/40 mg 90 IL CA JS
01-23-2007 732571 butalbital/APAP/caffeine 50/325/40 mg 90 IA CA JS
01-24-2007 733420 butalbital/APAP/caffeine 50/325/40 mg 90 NC CA JS
01-24-2007 733456 butalbital/APAP/caffeine 50/325/40 mg 30 MI CA JS
01-24-2007 733468 butalbital/APAP/caffeine 50/325/40 mg 90 LA CA JS
01-25-2007 733787 butalbital/APAP/caffeine 50/325/40 mg 90 MA CA JS
22 of 154
Qty Pt. Pres.

01-25-2007 733829 butalbital/APAP/caffeine 50/325/40 mg 90 WA CA JS
01-25-2007 733850 butalbital/APAP/caffeine 50/325/40 mg 90 KS CA JS
01-26-2007 734003 butalbital/APAP/caffeine 50/325/40 mg 90 OK CA JS
01-29-2007 734324 butalbital/APAP/caffeine 50/325/40 mg 90 UT CA JS
01-29-2007 734387 butalbital/APAP/caffeine 50/325/40 mg 90 WI CA JS
01-29-2007 734400 butalbital/APAP/caffeine 50/325/40 mg 90 IN CA JS
01-31-2007 735099 butalbital/APAP/caffeine 50/325/40 mg 90 NM CA JS
01-31-2007 735460 butalbital/APAP/caffeine 50/325/40 mg 90 MS CA JS
23 of 154
Qty Pt. Pres.

02-12-2007 736730 butalbital/APAP/caffeine 50/325/40 mg 90 HI CA JS
02-12-2007 736756 butalbital/APAP/caffeine 50/325/40 mg 90 AZ CA JS
02-12-2007 738140 butalbital/APAP/caffeine 50/325/40 mg 90 NJ CA JS
02-12-2007 738406 butalbital/APAP/caffeine 50/325/40 mg 90 ME CA JS
02-12-2007 738417 butalbital/APAP/caffeine 50/325/40 mg 90 NE CA JS
02-13-2007 737017 butalbital/APAP/caffeine 50/325/40 mg 90 ID CA JS
02-26-2007 742069 butalbital/APAP/caffeine 50/325/40 mg 90 RI CA JS
02-26-2007 742170 butalbital/APAP/caffeine 50/325/40 mg 90 VT CA JS
24 of 154
Qty Pt. Pres.

02-27-2007 742601 butalbital/APAP/caffeine 50/325/40 mg 90 MN CA JS
02-27-2007 742603 butalbital/APAP/caffeine 50/325/40 mg 90 SC CA JS
25 of 154
Qty Pt. Pres.

03-16-2007 747346 butalbital/APAP/caffeine 50/325/40 mg 90 MO CA JS
03-19-2007 747739 butalbital/APAP/caffeine 50/325/40 mg 90 ND CA JS
03-22-2007 748972 butalbital/APAP/caffeine 50/325/40 mg MD CA JS
26 of 154
Qty Pt. Pres.

04-03-2007 751552 butalbital/APAP/caffeine 50/325/40 mg 90 DE CA JS
04-03-2007 752029 butalbital/APAP/caffeine 50/325/40 mg 90 OR CA JS
27 of 154
Qty Pt. Pres.

04-17-2007 755968 butalbital/APAP/caffeine 50/325/40 mg 90 DC CA JS
28 of 154
Qty Pt. Pres.

29 of 154
Qty Pt. Pres.

30 of 154
Qty Pt. Pres.

05-15-2007 764408 butalbital/APAP/caffeine 50/325/40 mg 90 AK CA JS
31 of 154
Qty Pt. Pres.

05-21-2007 766227 butalbital/APAP/caffeine 50/325/40 mg 90 FL CA JS
32 of 154
Qty Pt. Pres.

33 of 154
Qty Pt. Pres.

34 of 154
Qty Pt. Pres.

35 of 154
Qty Pt. Pres.

36 of 154
Qty Pt. Pres.

07-02-2007 779217 butalbital/APAP/caffeine 50/325/40 mg 90 MT CA JS
37 of 154
Qty Pt. Pres.

38 of 154
Qty Pt. Pres.

39 of 154
Qty Pt. Pres.

40 of 154
Qty Pt. Pres.

41 of 154
Qty Pt. Pres.

42 of 154
Qty Pt. Pres.

08-17-2007 4001168 butalbital/APAP/caffeine 50/325/40 mg 90 SD CA JS
43 of 154
Qty Pt. Pres.

08-20-2007 4001774 butalbital/APAP/caffeine 50/325/40 mg 90 VT CA JS
44 of 154
Qty Pt. Pres.

08-27-2007 5100793 butalbital/APAP/caffeine 50/325/40 mg 90 IL OK JS
08-27-2007 5100861 butalbital/APAP/caffeine 50/325/40 mg 90 NJ OK JS
08-27-2007 5100983 butalbital/APAP/caffeine 50/325/40 mg 90 LA OK JS
08-27-2007 5101104 butalbital/APAP/caffeine 50/325/40 mg 90 GA OK JS
08-27-2007 5101325 butalbital/APAP/caffeine 50/325/40 mg 90 NY OK JS
08-27-2007 5101833 butalbital/APAP/caffeine 50/325/40 mg 90 NM OK JS
08-27-2007 5103647 butalbital/APAP/caffeine 50/325/40 mg 90 CA OK JS
08-27-2007 5104095 butalbital/APAP/caffeine 50/325/40 mg 90 CT OK JS
08-27-2007 5104220 butalbital/APAP/caffeine 50/325/40 mg 90 PA OK JS
08-27-2007 5104472 butalbital/APAP/caffeine 50/325/40 mg 90 WI OK JS
08-27-2007 5104482 butalbital/APAP/caffeine 50/325/40 mg 90 OH OK JS
08-27-2007 5104616 butalbital/APAP/caffeine 50/325/40 mg 90 OR OK JS
08-27-2007 5104687 butalbital/APAP/caffeine 50/325/40 mg 90 SC OK JS
08-27-2007 5105002 butalbital/APAP/caffeine 50/325/40 mg 90 WA OK JS
08-27-2007 5105087 butalbital/APAP/caffeine 50/325/40 mg 90 ME OK JS
08-27-2007 5105211 butalbital/APAP/caffeine 50/325/40 mg 90 OK OK JS
08-27-2007 5105223 butalbital/APAP/caffeine 50/325/40 mg 90 VA OK JS
08-27-2007 5105250 butalbital/APAP/caffeine 50/325/40 mg 90 MA OK JS
08-27-2007 5105346 butalbital/APAP/caffeine 50/325/40 mg 90 CO OK JS
08-27-2007 5105375 butalbital/APAP/caffeine 50/325/40 mg 90 AZ OK JS
08-27-2007 5105390 butalbital/APAP/caffeine 50/325/40 mg 90 MN OK JS
08-28-2007 5104490 butalbital/APAP/caffeine 50/325/40 mg 90 NC OK JS
08-28-2007 5104741 butalbital/APAP/caffeine 50/325/40 mg 90 AK OK JS
45 of 154
Qty Pt. Pres.

08-28-2007 5105036 butalbital/APAP/caffeine 50/325/40 mg 90 TX OK JS
08-28-2007 5105145 butalbital/APAP/caffeine 50/325/40 mg 90 KS OK JS
08-28-2007 5105453 butalbital/APAP/caffeine 50/325/40 mg 30 UT OK JS
08-28-2007 5105887 butalbital/APAP/caffeine 50/325/40 mg 90 HI OK JS
08-28-2007 5105954 butalbital/APAP/caffeine 50/325/40 mg 90 AL OK JS
08-28-2007 5105963 butalbital/APAP/caffeine 50/325/40 mg 90 MI OK JS
08-28-2007 5106067 butalbital/APAP/caffeine 50/325/40 mg 90 NE OK JS
46 of 154
Qty Pt. Pres.

08-29-2007 5104730 butalbital/APAP/caffeine 50/325/40 mg 90 MD OK JS
08-29-2007 5106331 butalbital/APAP/caffeine 50/325/40 mg 90 RI OK JS
08-29-2007 5106344 butalbital/APAP/caffeine 50/325/40 mg 90 AR OK JS
08-29-2007 5106754 butalbital/APAP/caffeine 50/325/40 mg 90 FL OK JS
47 of 154
Qty Pt. Pres.

08-30-2007 5107693 butalbital/APAP/caffeine 50/325/40 mg 90 NH OK JS
08-30-2007 5107765 butalbital/APAP/caffeine 50/325/40 mg 90 WY OK JS
08-31-2007 5108196 butalbital/APAP/caffeine 50/325/40 mg 90 IN OK JS
48 of 154
Qty Pt. Pres.

09-04-2007 5108588 butalbital/APAP/caffeine 50/325/40 mg 90 HI OK JS
09-04-2007 5108757 butalbital/APAP/caffeine 50/325/40 mg 90 DC OK JS
09-04-2007 5108993 butalbital/APAP/caffeine 50/325/40 mg 90 DE OK JS
49 of 154
Qty Pt. Pres.

09-04-2007 5109572 butalbital/APAP/caffeine 50/325/40 mg 90 MO OK JS
50 of 154
Qty Pt. Pres.

09-06-2007 5111717 butalbital/APAP/caffeine 50/325/40 mg 90 VT OK JS
09-07-2007 5107191 butalbital/APAP/caffeine 50/325/40 mg 90 DE OK JS
09-07-2007 5112327 butalbital/APAP/caffeine 50/325/40 mg 90 ID OK JS
09-07-2007 5112332 butalbital/APAP/caffeine 50/325/40 mg 90 MS OK JS
51 of 154
Qty Pt. Pres.

09-11-2007 5113765 butalbital/APAP/caffeine 50/325/40 mg 90 KY OK JS
09-11-2007 5114042 butalbital/APAP/caffeine 50/325/40 mg 90 DC OK JS
09-12-2007 5109677 butalbital/APAP/caffeine 50/325/40 mg 90 MT OK JS
52 of 154
Qty Pt. Pres.

09-12-2007 5115009 butalbital/APAP/caffeine 50/325/40 mg 90 MS OK JS
Qty Pt. Pres.

1/10/2007 730049 carisoprodol 350 mg 90 CA CA JS
1/17/2007 728033 carisoprodol 350 mg 30 MS CA JS
1/17/2007 729885 carisoprodol 350 mg 90 CA CA JS
1/17/2007 730366 carisoprodol 350 mg 90 WA CA JS
1/19/2007 732254 carisoprodol 350 mg 90 NY CA JS
(10)Jonathan Price Shelton did, from January 10, 2007, through September 12, 2007, sell a
Qty Pt. Pres.

03-27-2007 749934 Cialis 20 mg 15 DC CA JS
03-28-2007 750367 Cialis 20 mg 15 NH CA JS
03-29-2007 750818 Cialis 20 mg 20 IN CA JS
03-30-2007 751198 Cialis 20 mg 20 MD CA JS
53 of 154
Qty Pt. Pres.

04-02-2007 751470 Cialis 20 mg 20 CA CA JS
04-02-2007 751480 Cialis 20 mg 20 OK CA JS
04-03-2007 752074 Cialis 20 mg 20 VA CA JS
04-03-2007 752094 Cialis 20 mg 10 NC CA JS
04-05-2007 752690 Cialis 20 mg 10 TX CA JS
Qty Pt. Pres.

01-17-2007 728033 cyclobenzaprine 10 mg 90 MS CA JS
04-10-2007 753131 cyclobenzaprine 10 mg 90 WY CA JS
04-23-2007 755308 cyclobenzaprine 10 mg 90 SC CA JS
04-27-2007 759367 cyclobenzaprine 10 mg 90 GA CA JS
04-27-2007 759368 cyclobenzaprine 10 mg 60 CA CA JS
05-02-2007 760147 cyclobenzaprine 10 mg 90 TX CA JS
05-02-2007 760194 cyclobenzaprine 10 mg 90 MD CA JS
05-02-2007 760424 cyclobenzaprine 10 mg 30 PA CA JS
05-03-2007 761015 cyclobenzaprine 10 mg 90 MA CA JS
05-03-2007 761024 cyclobenzaprine 10 mg 90 IL CA JS
05-21-2007 765952 cyclobenzaprine 10 mg 90 AZ CA JS
06-22-2007 776358 cyclobenzaprine 10 mg 30 NY CA JS
06-25-2007 776730 cyclobenzaprine 10 mg 90 MI CA JS
07-02-2007 779267 cyclobenzaprine 10 mg 90 IN CA JS
07-05-2007 780431 cyclobenzaprine 10 mg 90 CO CA JS
07-19-2007 785049 cyclobenzaprine 10 mg 90 NE CA JS
07-19-2007 785067 cyclobenzaprine 10 mg 90 UT CA JS
07-19-2007 785226 cyclobenzaprine 10 mg 90 WI CA JS
07-23-2007 781870 cyclobenzaprine 10 mg 90 WA CA JS
07-31-2007 789010 cyclobenzaprine 10 mg 90 NJ CA JS
08-06-2007 790776 cyclobenzaprine 10 mg 90 IN CA JS
08-07-2007 789436 cyclobenzaprine 10 mg 90 NJ CA JS
08-13-2007 793051 cyclobenzaprine 10 mg 90 AR CA JS
08-15-2007 4000275 cyclobenzaprine 10 mg 90 PA CA JS
08-20-2007 4001440 cyclobenzaprine 10 mg 90 DC CA JS
08-28-2007 5105898 cyclobenzaprine 10 mg 90 PA OK JS
09-04-2007 5108786 cyclobenzaprine 10 mg 90 CA OK JS
54 of 154
Qty Pt. Pres.

09-04-2007 5109070 cyclobenzaprine 10 mg 90 CO OK JS
09-11-2007 5114246 cyclobenzaprine 10 mg 60 GA OK JS
09-11-2007 5114314 cyclobenzaprine 10 mg 90 OK OK JS
09-12-2007 5115421 cyclobenzaprine 10 mg 90 MN OK JS
Qty Pt. Pres.

04-24-2007 758106 Effexor XR 37.5 mg 30 TX CA JS
07-18-2007 783715 Effexor XR 37.5 mg 30 UT CA JS
07-26-2007 787356 Effexor XR 37.5 mg 30 CA CA JS
08-31-2007 5107941 Effexor XR 37.5 mg 30 CA CA JS
(13)Jonathan Price Shelton did, from January 10, 2007, through September 12, 2007, sell a dangerous
drug when the conduct was not in accordance with Chapters 4729. and 4731. of the Ohio Revised
Code, to wit: Jonathan Price Shelton admittedly sold the following prescriptions pursuant to internet
sales without a valid physician-patient relationship:
Qty Pt. Pres.

06-28-2007 766820 Effexor XR 75 mg 30 AZ CA JS
07-09-2007 780792 Effexor XR 75 mg 90 IL CA JS
07-30-2007 788198 Effexor XR 75 mg 30 AZ CA JS
Qty Pt. Pres.

08-01-2007 789546 Effexor XR 150 mg 90 IL CA JS
(15)Jonathan Price Shelton did, from January 10, 2007, through September 12, 2007, sell a dangerous
drug when the conduct was not in accordance with Chapters 4729. and 4731. of the Ohio Revised
Code, to wit: Jonathan Price Shelton admittedly sold the following prescriptions pursuant to internet
sales without a valid physician-patient relationship:
Qty Pres.
Date Filled Script# Drug Strength Disp. Pt. State State R.Ph.
09-04-2007 5109189 Elavil 150 mg 90 GA OK JS
55 of 154
Qty Pres.
Date Filled Script# Drug Strength Disp. Pt. State State R.Ph.
09-06-2007 5111183 Elavil 150 mg 90 LA OK JS
09-12-2007 5114836 Elavil 150 mg 90 CO OK JS
Qty Pt. Pres.

03-05-2007 743993 Esgic Plus 50/500/40 mg 90 LA CA JS
03-06-2007 744459 Esgic Plus 50/500/40 mg 90 TX CA JS
03-28-2007 750342 Esgic Plus 50/500/40 mg 90 OH CA JS
04-09-2007 751601 Esgic Plus 50/500/40 mg 90 NY CA JS
04-30-2007 759596 Esgic Plus 50/500/40 mg 90 NC CA JS
05-11-2007 763478 Esgic Plus 50/500/40 mg 90 IL CA JS
05-16-2007 764914 Esgic Plus 50/500/40 mg 30 NM CA JS
05-25-2007 767948 Esgic Plus 50/500/40 mg 90 TX CA JS
06-14-2007 771680 Esgic Plus 50/500/40 mg 90 NC CA JS
06-25-2007 776745 Esgic Plus 50/500/40 mg 90 WI CA JS
07-02-2007 779256 Esgic Plus 50/500/40 mg 90 CA CA JS
07-03-2007 779714 Esgic Plus 50/500/40 mg 90 CA CA JS
07-18-2007 784781 Esgic Plus 50/500/40 mg 90 MS CA JS
07-19-2007 785261 Esgic Plus 50/500/40 mg 90 NY CA JS
07-26-2007 787636 Esgic Plus 50/500/40 mg 90 WA CA JS
08-31-2007 5108142 Esgic Plus 50/500/40 mg 90 ME OK JS
09-12-2007 5112048 Esgic Plus 50/500/40 mg 90 NY OK JS
Qty Pt. Pres.

04-03-2007 752036 fluoxetine 20 mg 90 CA CA JS
04-20-2007 757179 fluoxetine 20 mg 90 AZ CA JS
05-11-2007 763499 fluoxetine 20 mg 90 IL CA JS
06-11-2007 772475 fluoxetine 20 mg 90 TX CA JS
56 of 154
Qty Pt. Pres.

07-23-2007 786136 fluoxetine 20 mg 90 AZ CA JS
08-30-2007 5107675 fluoxetine 20 mg 90 PA OK JS
the Ohio Revised Code, to wit: Jonathan Price Shelton u admittedly sold the following
Qty Pt. Pres.

06-06-2007 749567 Imitrex Oral 50 mg 27 CA CA JS
06-06-2007 751929 Imitrex Oral 50 mg 9 NJ CA JS
06-06-2007 754721 Imitrex Oral 50 mg 9 KS CA JS
08-20-2007 4001691 Imitrex Oral 50 mg 9 KS CA JS
Qty Pt. Pres.

04-05-2007 752750 Propecia 1 mg 60 CT CA JS
04-16-2007 755406 Propecia 1 mg 90 NY CA JS
04-16-2007 755600 Propecia 1 mg 90 CA CA JS
04-27-2007 759356 Propecia 1 mg 90 NJ CA JS
05-23-2007 767135 Propecia 1 mg 90 TX CA JS
05-29-2007 768187 Propecia 1 mg 30 DC CA JS
05-30-2007 769118 Propecia 1 mg 90 OH CA JS
06-06-2007 771041 Propecia 1 mg 60 CT CA JS
06-08-2007 771804 Propecia 1 mg 90 CO CA JS
06-27-2007 777830 Propecia 1 mg 90 PA CA JS
06-29-2007 778691 Propecia 1 mg 60 RI CA JS
08-06-2007 790630 Propecia 1 mg 90 HI CA JS
08-23-2007 4003145 Propecia 1 mg 90 TX CA JS
08-27-2007 5105362 Propecia 1 mg 90 CA OK JS
08-31-2007 5107569 Propecia 1 mg 90 MA OK JS
09-06-2007 5111921 Propecia 1 mg 30 OR OK JS
09-11-2007 5111496 Propecia 1 mg 60 CA OK JS
57 of 154
Qty Pt. Pres.

01-10-2007 730105 tramadol 50 mg 90 CA CA JS
01-11-2007 730430 tramadol 50 mg 90 OR CA 1234
01-11-2007 730443 tramadol 50 mg 180 NY CA 1234
01-11-2007 730518 tramadol 50 mg 30 AK CA 1234
01-12-2007 727374 tramadol 50 mg 180 NJ CA JS
01-12-2007 727378 tramadol 50 mg 180 TX CA JS
01-15-2007 730903 tramadol 50 mg 90 OK CA JS
01-15-2007 731006 tramadol 50 mg 90 MA CA JS
01-16-2007 730868 tramadol 50 mg 180 MI CA JS
01-16-2007 730879 tramadol 50 mg 180 DE CA JS
01-16-2007 730896 tramadol 50 mg 180 CT CA JS
01-16-2007 730897 tramadol 50 mg 180 NM CA JS
01-16-2007 730908 tramadol 50 mg 180 GA CA JS
01-17-2007 731615 tramadol 50 mg 180 IL CA JS
01-17-2007 731656 tramadol 50 mg 180 OH CA JS
01-17-2007 731660 tramadol 50 mg 180 MO CA JS
01-18-2007 731377 tramadol 50 mg 180 NY CA JS
01-19-2007 732311 tramadol 50 mg 90 AR CA JS
01-22-2007 732481 tramadol 50 mg 180 ID CA JS
01-22-2007 732589 tramadol 50 mg 90 PA CA JS
01-22-2007 732682 tramadol 50 mg 90 AZ CA JS
01-22-2007 732700 tramadol 50 mg 90 WA CA JS
01-23-2007 732663 tramadol 50 mg 90 IN CA JS
01-24-2007 733453 tramadol 50 mg 180 KY CA JS
01-24-2007 733479 tramadol 50 mg 180 CO CA JS
01-24-2007 733485 tramadol 50 mg 180 AL CA JS
58 of 154
Qty Pt. Pres.

01-25-2007 733805 tramadol 50 mg 180 NE CA JS
01-26-2007 733942 tramadol 50 mg 180 VA CA JS
02-01-2007 735441 tramadol 50 mg 180 ND CA JS
02-01-2007 735442 tramadol 50 mg 180 MD CA JS
02-01-2007 735736 tramadol 50 mg 180 RI CA JS
02-01-2007 735873 tramadol 50 mg 180 AK CA JS
02-02-2007 735960 tramadol 50 mg 180 LA CA JS
02-02-2007 735992 tramadol 50 mg 180 KS CA JS
02-05-2007 736462 tramadol 50 mg 180 SC CA JS
02-07-2007 737449 tramadol 50 mg 180 NV CA JS
02-07-2007 737476 tramadol 50 mg 180 UT CA JS
59 of 154
Qty Pt. Pres.

02-08-2007 737673 tramadol 50 mg 180 WI CA JS
02-08-2007 737677 tramadol 50 mg 180 NC CA JS
02-09-2007 737675 tramadol 50 mg 180 OR CA JS
02-13-2007 738350 tramadol 50 mg 180 NH CA JS
02-15-2007 738961 tramadol 50 mg 180 MN CA JS
60 of 154
Qty Pt. Pres.

02-19-2007 740079 tramadol 50 mg 180 HI CA JS
02-21-2007 738900 tramadol 50 mg 180 MS CA JS

02-23-2007 741816 tramadol 50 mg 180 VT CA JS
02-26-2007 741885 tramadol 50 mg 180 MT CA JS
61 of 154

62 of 154

03-08-2007 743097 tramadol 50 mg 180 ME CA JS
63 of 154

03-14-2007 746724 tramadol 50 mg 180 IA CA JS
64 of 154

65 of 154

66 of 154

03-28-2007 750084 tramadol 50 mg 180 FL CA JS
67 of 154

68 of 154

69 of 154

70 of 154

04-13-2007 755057 tramadol 50 mg 180 SD CA JS
71 of 154

72 of 154

73 of 154

74 of 154

75 of 154

76 of 154

77 of 154

78 of 154

79 of 154

80 of 154

81 of 154

82 of 154

83 of 154

84 of 154

85 of 154

86 of 154

87 of 154

88 of 154

89 of 154

90 of 154

91 of 154

06-07-2007 771511 tramadol 50 mg 180 WY CA JS
92 of 154

93 of 154

94 of 154

95 of 154

96 of 154

97 of 154

98 of 154

99 of 154

100 of 154

101 of 154

102 of 154

103 of 154

104 of 154

105 of 154

106 of 154

07-16-2007 783543 tramadol 50 mg 180 WV CA JS
107 of 154

108 of 154

109 of 154

110 of 154

111 of 154

112 of 154

113 of 154

114 of 154

115 of 154

116 of 154

117 of 154

118 of 154

119 of 154

120 of 154

121 of 154

122 of 154

123 of 154

08-17-2007 4001162 tramadol 50 mg 90 WY CA JS
124 of 154

125 of 154

126 of 154

127 of 154

08-27-2007 5095745 tramadol 50 mg 180 WA OK JS
08-27-2007 5100049 tramadol 50 mg 180 GA OK JS
08-27-2007 5100558 tramadol 50 mg 180 CT OK JS
08-27-2007 5100986 tramadol 50 mg 180 OH OK JS
08-27-2007 5101171 tramadol 50 mg 180 OR OK JS
08-27-2007 5101273 tramadol 50 mg 180 PA OK JS
08-27-2007 5101274 tramadol 50 mg 180 CA OK JS
08-27-2007 5101788 tramadol 50 mg 180 NJ OK JS
08-27-2007 5103850 tramadol 50 mg 180 WI OK JS
08-27-2007 5104039 tramadol 50 mg 180 NY OK JS
08-27-2007 5104085 tramadol 50 mg 180 LA OK JS
08-27-2007 5104134 tramadol 50 mg 180 IN OK JS
128 of 154

08-27-2007 5104435 tramadol 50 mg 180 TX OK JS
08-27-2007 5104473 tramadol 50 mg 180 IL OK JS
08-27-2007 5104665 tramadol 50 mg 180 AZ OK JS
08-27-2007 5104756 tramadol 50 mg 180 NC OK JS
08-27-2007 5104842 tramadol 50 mg 180 MI OK JS
08-27-2007 5104852 tramadol 50 mg 180 NM OK JS
08-27-2007 5104855 tramadol 50 mg 180 CO OK JS
08-27-2007 5104957 tramadol 50 mg 180 VA OK JS
08-27-2007 5105132 tramadol 50 mg 90 NH OK JS
08-27-2007 5105339 tramadol 50 mg 180 MN OK JS
08-27-2007 5105398 tramadol 50 mg 90 MS OK JS
08-27-2007 5105401 tramadol 50 mg 180 MD OK JS
08-28-2007 5097442 tramadol 50 mg 180 OK OK JS
08-28-2007 5105331 tramadol 50 mg 180 UT OK JS
129 of 154

08-28-2007 5105381 tramadol 50 mg 90 ID OK JS
08-28-2007 5105438 tramadol 50 mg 180 KS OK JS
08-28-2007 5105473 tramadol 50 mg 180 AK OK JS
08-28-2007 5105591 tramadol 50 mg 180 MA OK JS
08-28-2007 5105631 tramadol 50 mg 180 DE OK JS
08-28-2007 5105681 tramadol 50 mg 180 AL OK JS
08-29-2007 5097092 tramadol 50 mg 180 AR OK JS
130 of 154

08-29-2007 5106267 tramadol 50 mg 180 ME OK JS
08-29-2007 5106314 tramadol 50 mg 180 NE OK JS
08-29-2007 5106558 tramadol 50 mg 180 SC OK JS
08-29-2007 5106604 tramadol 50 mg 180 IA OK JS
131 of 154

08-30-2007 5103858 tramadol 50 mg 180 MT OK JS
132 of 154

08-30-2007 5107654 tramadol 50 mg 180 TN OK JS
08-30-2007 5107657 tramadol 50 mg 180 NV OK JS
133 of 154

134 of 154

08-31-2007 5108165 tramadol 50 mg 90 VT OK JS
08-31-2007 5108183 tramadol 50 mg 180 MO OK JS
08-31-2007 5108187 tramadol 50 mg NY OK JS
135 of 154

09-04-2007 5108143 tramadol 50 mg 180 ND OK JS
136 of 154

09-04-2007 5108783 tramadol 50 mg 180 NV OK JS
137 of 154

09-05-2007 5110147 tramadol 50 mg 180 HI OK JS
138 of 154

139 of 154

09-06-2007 5111613 tramadol 50 mg 180 TN OK JS
09-06-2007 5111642 tramadol 50 mg 180 RI OK JS
140 of 154

141 of 154

142 of 154

09-10-2007 5112772 tramadol 50 mg 90 DC OK JS
143 of 154

09-10-2007 5113450 tramadol 50 mg 90 FL OK JS
144 of 154

09-11-2007 5114408 tramadol 50 mg MN OK JS
09-11-2007 5114443 tramadol 50 mg 180 WY OK JS
145 of 154

09-12-2007 5115016 tramadol 50 mg 180 FL OK JS
09-12-2007 5115021 tramadol 50 mg 180 KY OK JS
146 of 154

Qty Pt. Pres.

03-23-2007 749144 tramadol hydrochloride/APAP 37.5/325 mg 90 CA OK JS
03-26-2007 749763 tramadol hydrochloride/APAP 37.5/325 mg 90 MS OK JS
03-27-2007 749969 tramadol hydrochloride/APAP 37.5/325 mg 90 IN OK JS
03-28-2007 750370 tramadol hydrochloride/APAP 37.5/325 mg 60 VA OK JS
03-28-2007 750422 tramadol hydrochloride/APAP 37.5/325 mg 90 OK OK JS
04-03-2007 752022 tramadol hydrochloride/APAP 37.5/325 mg 90 NY OK JS
04-03-2007 752122 tramadol hydrochloride/APAP 37.5/325 mg 90 CO OK JS
04-04-2007 752407 tramadol hydrochloride/APAP 37.5/325 mg 60 MD OK JS
04-05-2007 752659 tramadol hydrochloride/APAP 37.5/325 mg 90 IL OK JS
04-23-2007 757600 tramadol hydrochloride/APAP 37.5/325 mg 60 GA OK JS
04-24-2007 758038 tramadol hydrochloride/APAP 37.5/325 mg 60 NJ OK JS
04-27-2007 759360 tramadol hydrochloride/APAP 37.5/325 mg 30 OH OK JS
05-02-2007 760676 tramadol hydrochloride/APAP 37.5/325 mg 30 CT OK JS
05-10-2007 763095 tramadol hydrochloride/APAP 37.5/325 mg 60 PA OK JS
05-24-2007 766711 tramadol hydrochloride/APAP 37.5/325 mg 60 NE OK JS
05-29-2007 768795 tramadol hydrochloride/APAP 37.5/325 mg 90 SC OK JS
05-29-2007 768859 tramadol hydrochloride/APAP 37.5/325 mg 90 LA OK JS
05-31-2007 769807 tramadol hydrochloride/APAP 37.5/325 mg 90 UT OK JS
147 of 154
Qty Pt. Pres.

06-12-2007 772746 tramadol hydrochloride/APAP 37.5/325 mg 90 MI OK JS
06-12-2007 772803 tramadol hydrochloride/APAP 37.5/325 mg 60 TX OK JS
06-26-2007 777374 tramadol hydrochloride/APAP 37.5/325 mg 60 IA OK JS
07-03-2007 779765 tramadol hydrochloride/APAP 37.5/325 mg 90 AL OK JS
07-09-2007 781117 tramadol hydrochloride/APAP 37.5/325 mg 90 NC OK JS
07-09-2007 781443 tramadol hydrochloride/APAP 37.5/325 mg 90 WA OK JS
07-13-2007 783283 tramadol hydrochloride/APAP 37.5/325 mg 60 ND OK JS
07-26-2007 787165 tramadol hydrochloride/APAP 37.5/325 mg 90 TN OK JS
07-30-2007 788551 tramadol hydrochloride/APAP 37.5/325 mg 90 IA OK JS
08-06-2007 790764 tramadol hydrochloride/APAP 37.5/325 mg 90 AL OK JS
148 of 154
Qty Pt. Pres.

08-16-2007 4000769 tramadol hydrochloride/APAP 37.5/325 mg 90 ND OK JS
08-21-2007 4002248 tramadol hydrochloride/APAP 37.5/325 mg 90 MA OK JS
08-27-2007 5105393 tramadol hydrochloride/APAP 37.5/325 mg 60 OR OK JS
08-30-2007 5103639 tramadol hydrochloride/APAP 37.5/325 mg 90 DE OK JS
08-30-2007 5107476 tramadol hydrochloride/APAP 37.5/325 mg 90 KS OK JS
09-04-2007 5108977 tramadol hydrochloride/APAP 37.5/325 mg 90 NC OK JS
09-10-2007 5113452 tramadol hydrochloride/APAP 37.5/325 mg 90 MD OK JS
After a thorough review of the physical evidence presented, it is clear to this Board that these
prescriptions, when presented to a pharmacist for filling, warranted further inquiry by the
pharmacist to whom they were presented for filling. All pharmacists are trained to know that they
must, as required by state regulation as well as professional training and experience, inquire into
the legitimacy and appropriateness of the prescriptions. These prescriptions, in the professional
opinion of this Board, are not written for a legitimate medical purpose and should not have been
dispensed. It is clear to this Board that Mr. Shelton knew or should have known this, and he
willingly turned a "blind eye" to his responsibility to refuse to fill these prescriptions.
It is noteworthy that, when questioned by a Board member, Mr. Shelton admitted that, in a retail
practice setting, had he done what is normal practice - i.e. call the physician to inquire about the
scope of the physician's practice, he would have acted differently. This simply means he did not
practice pharmacy as he should have, and had he done so he would have acted differently.
These drugs should not have been dispensed.
The Board further finds that Mr. Shelton's testimony is self-serving, incorrect in assumption, and
is unreliable. For example, Mr. Shelton's characterization of "telemedicine" is factually incorrect
inasmuch as he only uses a small portion of a very large picture to attempt to justify his position,
yet he cannot do so.
149 of 154
Mr. Shelton's attorney asserts that since Mr. Shelton was found Not Guilty in the criminal system
he should not be held accountable to this Board. Nothing could be further from the truth. This
Board is comprised of experts in the practice of pharmacy and intimately understands the proper
and legal practice of pharmacy. A review of the prescriptions in question clearly shows that Mr.
Shelton acted improperly when he filled them.
CONCLUSIONS OF LAW
Fact constitute being guilty of gross immorality as provided in Division (A)(1) of Section
Fact constitute being guilty of dishonesty and unprofessional conduct in the practice of
pharmacy as provided in Division (A)(2) of Section 4729.16 of the Ohio Revised Code.
Fact constitute being guilty of willfully violating, conspiring to violate, attempting to violate, or
aiding and abetting the violation of provisions of Chapter 2925. of the Revised Code as
provided in Division (A)(5) of Section 4729.16 of the Ohio Revised Code.
whole, the State Board of Pharmacy adjudicates the matter of Jonathan Price Shelton as follows:
(A) On the basis of the Findings of Fact and paragraph (1) of the Conclusions of Law, the State
Board of Pharmacy hereby revokes permanently the pharmacist identification card, No. 03-3-
11927, held by Jonathan Price Shelton effective as of the date of the mailing of this Order.
(B) On the basis of the Findings of Fact and paragraph (2) of the Conclusions of Law, the State
(C) On the basis of the Findings of Fact and paragraph (3) of the Conclusions of Law, the State
Jonathan Price Shelton, pursuant to Section 4729.16(B) of the Ohio Revised Code, must return
his license to practice (pocket ID card) and registration (wall certificate) to the office of the State
Board of Pharmacy within ten days after receipt of this Order unless the Board office is already in
possession of both. The identification card and wall certificate should be sent by certified mail,
return receipt requested.
Elizabeth I. Gregg moved for Findings of Fact; Heather L. Pasquale seconded the motion. Motion
Elizabeth I. Gregg moved for Conclusions of Law; Deborah A. Lange seconded the motion.
Deborah A. Lange moved for Action of the Board; Heather L. Pasquale seconded the motion.
3:12 p.m. The Board recessed briefly.

150 of 154
3:16 p.m. The Board was joined by Assistant Attorney General Tracy Marie Greuel to conduct an
matter of Ryan Andrew Stout, R.Ph. (03-3-29086) Akron, Ohio.
Revised Code. The motion was seconded by Mr. Wiesenhahn and a roll-call vote was
conducted by President Lipsyc as follows: Braylock – yes; Casar – yes; Gregg – yes; Kaderly –
yes; Kolezynski – yes; Lange – yes; Pasquale – yes; and Wiesenhahn – yes.
Ryan Andrew Stout, R.Ph. (03-3-29086) Akron, Ohio.

in the matter of:
RYAN ANDREW STOUT, R.Ph.

452 E. Walnut Street
Perkasie, PA 18944
R.Ph. Number 03-3-29086
INTRODUCTION
The matter of Ryan Andrew Stout came for hearing on June 10, 2009, before the following
members of the Board: Nathan S. Lipsyc, R.Ph. (presiding); Gregory Braylock, R.Ph.; Donald M.
Casar, R.Ph.; Elizabeth I. Gregg, R.Ph.; Barton G. Kaderly, Public Member; Richard F.
Kolezynski, R.Ph.; Deborah A. Lange, R.Ph.; Heather L. Pasquale, R.Ph.; and Jerome J.
Wiesenhahn, R.Ph.
Ryan Andrew Stout was represented by Robert J. Garrity. The State of Ohio was represented by
Tracy Marie Greuel, Assistant Attorney General.
SUMMARY OF EVIDENCE
State’s Witnesses: Paul Kover, Ohio State Board of Pharmacy

Ryan Andrew Stout, R.Ph., Respondent
Respondent's Witness: Ryan Andrew Stout, R.Ph., Respondent
State's Exhibits:
1. Copy of Summary Suspension Order/Notice of Opportunity For Hearing letter [02-04-09]
1A-1E. Procedurals
2. Notarized Statement of Ryan Stout [01-20-09]
3. Notarized Statement of Lee Bragg [01-20-09]
4. Pharmacy Employee Schedule at Medina General Hospital [01-11-09 through 01-24-09]
5. Eleven photographs taken by Medina General Hospital Security [01-15-09]
6. One empty Unit Dose Card of hydrocodone 5 mg/APAP 500 mg, taken from Respondent
[01-20-09]
151 of 154
A. PRO Pharmacist's Recovery Contract for Ryan Stout [04-08-09]
B. Letter and Treatment Documentation from David Newton-Gatts LICDC at Cleveland Clinic
affiliate Glenbeigh [07-09-09]
C. Support Group Attendance Records [03-02-09 to 06-09-09]
D. First Lab OHPRO Test History Report [05-30-09]; Glenbeigh Drug Screen Reports [04-04-
09 and 05-10-09]
E. CVS #0305 Employee Maintenance Computer Screen Printout; Signed Statement of Ryan
Stout; Notice of Civil Demand in re Ryan Stout; Promissory Note in re Ryan Stout [07-10-08];
Miscellaneous Page of Figures [07-10-08]; Indictment, State of Ohio vs. Ryan A. Stout, Case
No. 09CR0099, Medina County Common Pleas Court; Prosecuting Attorney's Request for
Issuance of Warrant Upon Indictment; Bond Recommendation [03-04-09]; Judgment Entry
Fixing Bond; Warrant on Indictment [03-09-09]; General Index Case Detail [06-05-09]
F. Restitution Documentation [10-03-08 to 06-05-09]
G. Four Letters of Support [05-28-09 to 06-03-09]
H. Continuing Pharmaceutical Education Credits and Certificates [05-03-09 to 05-28-09]
FINDINGS OF FACT
After having heard the testimony, observed the demeanor of the witnesses, considered the
evidence, and weighed the credibility of each, the State Board of Pharmacy finds the following to
be fact:
(1) Records of the Board of Pharmacy indicate that Ryan Andrew Stout was originally licensed in
the State of Ohio on November 25, 2008, pursuant to examination, and his license to practice
pharmacy in Ohio was summarily suspended on February 4, 2009.
(2) Ryan Andrew Stout is addicted to or abusing drugs and/or impaired physically or mentally to
such a degree as to render him unfit to practice pharmacy, to wit: Ryan Andrew Stout has
admitted to being addicted to hydrocodone. Ryan Andrew Stout has admitted to stealing
hydrocodone with APAP products from his employer to support his addiction. Ryan Andrew
Stout indicated that he started stealing drugs in October or November of 2008, and he
ingested approximately 8 tablets per day. Ryan Andrew Stout has admitted to consuming
hydrocodone while practicing pharmacy. Such conduct indicates that Ryan Andrew Stout is
within the ambit of Sections 3719.121 and/or 4729.16(A)(3) of the Ohio Revised Code.
(3) Ryan Andrew Stout did, from January 13, 2009, through January 19, 2009, with purpose to
deprive, knowingly obtain or exert control over dangerous drugs, the property of Medina
General Hospital, beyond the express or implied consent of the owner, to wit: Ryan Andrew
Stout admitted to Board agents that he stole approximately 332 hydrocodone 5 mg with
APAP 500 mg tablets and a 15 ml bottle of hydrocodone 7.5 mg with APAP 500 mg. liquid.
Such conduct is in violation of Section 2913.02 of the Ohio Revised Code.
CONCLUSIONS OF LAW
constitutes being guilty of gross immorality as provided in Division (A)(1) of Section 4729.16
of the Ohio Revised Code.
constitutes being guilty of dishonesty and unprofessional conduct in the practice of pharmacy
as provided in Division (A)(2) of Section 4729.16 of the Ohio Revised Code.
constitutes being addicted to or abusing liquor or drugs or impaired physically or mentally to
such a degree as to render him unfit to practice pharmacy as provided in Division (A)(3) of
Section 4729.16 of the Ohio Revised Code.
152 of 154
Pursuant to Section 3719.121 of the Ohio Revised Code, the State Board of Pharmacy hereby
removes the Summary Suspension Order issued to Ryan Andrew Stout on February 4, 2009.
whole, the State Board of Pharmacy hereby suspends indefinitely the pharmacist identification
card, No. 03-3-29086, held by Ryan Andrew Stout and such suspension is effective as of the date
of the mailing of this Order.
(A) Ryan Andrew Stout, pursuant to Rule 4729-9-01(F) of the Ohio Administrative Code, may not
be employed by or work in a facility licensed by the State Board of Pharmacy to possess or
distribute dangerous drugs during such period of suspension.
(B) Ryan Andrew Stout, pursuant to Section 4729.16(B) of the Ohio Revised Code, must return
his identification card and license (wall certificate) to the office of the State Board of
Pharmacy within ten days after receipt of this Order unless the Board office is already in
possession of both. The identification card and wall certificate should be sent by certified
mail, return receipt requested.
Further, the Board will not consider any petition filed by Ryan Andrew Stout for a hearing,
pursuant to Ohio Revised Code Chapter 119., for reinstatement, prior to February 4, 2011. The
Board will only consider reinstatement of the license to practice pharmacy in Ohio if the following
conditions have been met:
(A) Ryan Andrew Stout must enter into a new contract, signed within thirty days after the
effective date of this Order, with an Ohio Department of Alcohol and Drug Addiction Services
(ODADAS) treatment provider or a treatment provider acceptable to the Board for a period of
not less than five years and submit a copy of the signed contract to the Board office. The
contract must provide that:
(1) Random, observed urine drug screens shall be conducted at least once each month.
(a) The urine sample must be given within twelve hours of notification. The urine drug
screen must include testing for creatinine or specific gravity of the sample as the
dilutional standard.
(b) Results of all drug screens must be negative. Refusal of a drug screen or a diluted
drug screen is equivalent to a positive result. Any positive results, including those
which may have resulted from ingestion of food, but excluding false positives which
resulted from medication legitimately prescribed, indicates a violation of the contract.
(2) The intervener/sponsor shall submit reports to the Board, in a format acceptable to the
Board, indicating drug screens and their results in a timely fashion. Actual copies of drug
screens shall be made available to the Board upon request.
(3) Attendance is required a minimum of three times per calendar week at an Alcoholics
Anonymous, Narcotics Anonymous, and/or similar support group meeting.
(4) The program shall immediately report to the Board any violations of the contract and/or
lack of cooperation.
(B) Ryan Andrew Stout must demonstrate satisfactory proof to the Board that he is no longer
addicted to or abusing drugs or impaired physically or mentally to such a degree as to render
him unfit to practice pharmacy.
153 of 154
(C) Ryan Andrew Stout must provide, at the reinstatement petition hearing, documentation of the
following:
(1) Compliance with the contract required above (e.g.-proof of giving the sample within
twelve hours of notification and copies of all drug screen reports, meeting attendance
records, treatment program reports, etc.);
(2) Compliance with the continuing pharmacy education requirements set forth in Chapter
4729-7 of the Ohio Administrative Code as applicable and in effect on the date of
petitioning the Board for reinstatement;
(3) Compliance with the terms of this Order.
(D) If reinstatement is not accomplished within three years of the effective date of this Order,
Ryan Andrew Stout must also show successful completion of the North American Pharmacist
Licensure Examination (NAPLEX) examination.
(E) Upon such time as the Board may consider reinstatement, Ryan Andrew Stout will be
afforded a Chapter 119. hearing. At such time, the Board may consider reinstatement with or
without restrictions and/or conditions as the Board deems appropriate under the
circumstances.
Elizabeth I. Gregg moved for Findings of Fact; Deborah A. Lange seconded the motion. Motion
Elizabeth I. Gregg moved for Conclusions of Law; Richard F. Kolezynski seconded the motion.
Gregory Braylock moved for Action of the Board; Deborah A. Lange seconded the motion.
R-2009-295 After discussion, Mr. Casar moved that the Millennium Pharmacy Systems request for remote
processing be found approvable pending final inspection; the Board requested notification
when the final inspection in conducted. Ms. Lange seconded the motion and it was approved by
the Board: Aye –7; Abstain – 1 (Kaderly).
Revised Code. The motion was seconded by Mr. Casar and a roll-call vote was conducted by
President Lipsyc as follows: Braylock – yes; Casar – yes; Gregg – yes; Kaderly – yes; Kolezynski
– yes; Lange – yes; Pasquale – yes; and Wiesenhahn – yes.
5:33 p.m. Mrs. Gregg moved that the Board receive Per Diem as follows:
154 of 154
PER DIEM 5/11 5/26 6/5 6/8 6/9 6/10 Total

Braylock 1 - - 1 1 1 4
Casar - - - 1 1 1 3
Gregg - - - 1 1 1 3
Kaderly - - - 1 - 1 2
Kolezynski - 1 1 1 1 1 5
Lange - - - 1 1 1 3
Lipsyc - - - 1 1 1 3
Pasquale - - - 1 1 1 3
Wiesenhahn - 1 - 1 1 1 4
Mr. Casar seconded the motion and it was approved by the Board: Aye – 8.
President Lipsyc administered the Oath of Office to the president-elect, Elizabeth I. Gregg.
OATH OF PRESIDENT
I, Elizabeth I. Gregg, as President of the Ohio Board of Pharmacy, do solemnly

swear to uphold the Constitution of the United States and the state of Ohio; to
impartially enforce the laws governing the profession of pharmacy and the legal
distribution of drugs in the State of Ohio; and carry out the responsibilities of the
Board as mandated by the laws of the State of Ohio without bias or prejudice, so
help me God.
President Gregg then administered the Oath of Office to Vice-President-elect, Heather

L. Pasquale.
OATH OF VICE-PRESIDENT
I, Heather L. Pasquale, as Vice-President of the Ohio Board of Pharmacy, do

solemnly swear to uphold the Constitution of the United States and the state of
Ohio; to impartially enforce the laws governing the profession of pharmacy and
the legal distribution of drugs in the State of Ohio; and carry out the
responsibilities of the Board as mandated by the laws of the State of Ohio without
bias or prejudice, so help me God.
5:37 p.m. Mr. Kolezynski moved that the meeting be adjourned. The motion was seconded by
Ms. Lange and approved by the Board: Aye – 8.
The Ohio State Board of Pharmacy

approved these Minutes July 14, 2009
This public document is provided as a courtesy by:
James Lindon, Pharm.D., Ph.D., J.D., Attorney at Law

Lindon & Lindon, LLC
Patents, Trademarks, Copyright, Pharmacy Law
35104 Saddle Creek
Cleveland (Avon), Ohio 44011-4907
Phone: 440-333-0011
Fax: 419-710-4925
http://www.lindonlaw.com/
Publication of this document does not necessarily mean that the pharmacist or other
person mentioned in the document did what he/she is being accused of.

Mins 09060810 Ohio State Board of Pharmacy Minutes, Courtesy of Lindon & Lindon

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Mins 09060810 Ohio State Board of Pharmacy Minutes, Courtesy of Lindon & Lindon

Uploaded by

Copyright:

Available Formats

Note: These Minutes are provided for informational purposes only.

Minutes of the June 8-10, 2009

Monday, June 8, 2009

Nathan S. Lipsyc, R.Ph., President; Elizabeth I. Gregg, R.Ph., Vice-President; Donald M.

1:23 p.m. The Executive Session ended.

The meeting was recessed for lunch.

2:15 p.m. The Board reconvened with all members present.

ORDER OF THE STATE BOARD OF PHARMACY

in the matter of:

RAYMOND P. DENUIT, R.Ph.

R.Ph. Number 03-1-10793

Nathan S. Lipsyc, R.Ph., Board President, absent

Heather L. Pasquale, R.Ph., Board Member, absent

Raymond P. Denuit was represented by Elizabeth Y. Collis. The State of Ohio

State’s Witnesses; Kevin J. Kinneer, Ohio State Board of Pharmacy

Respondent's Witnesses: None

examination, and is currently licensed to practice pharmacy in the State of

DECISION OF THE BOARD

Board of Pharmacy, 77 South High Street, Room 1702, Columbus, Ohio

(1) Raymond P. Denuit, pursuant to Rule 4729-9-01(F) of the Ohio

(2) Raymond P. Denuit, pursuant to Section 4729.16(B) of the Ohio Revised

(B) Raymond P. Denuit must obtain sexual harassment in the workplace

(C) Upon reappearance Raymond P. Denuit, must affirmatively show compliance

Gregory Braylock moved for Conclusions of Law; Jerome Wiesenhahn seconded

Mr. Keeley presented the Legislative Report.

Rule No. Rule Title

CHAPTER 4729-5 [PHARMACY PRACTICE]

CHAPTER-37 [DRUG DATABASE]

FULL TEXT SHOWING CHANGES

UNDERLINED = Add New Language LINED THROUGH = Remove Old Language

4729-4-01 Definitions (Effective 6-21-09)

As used in Chapter 4729-4 of the Administrative Code:

4729-4-03 Qualified pharmacy technician training program (Effective 6-21-09)

(B) Pharmacy terminology;

(C) Basic drug information;

(D) Basic calculations;

(E) Quality control procedures;

(F) State and federal laws, rules, and regulations regarding:

(1) Qualified pharmacy technician duties;

(2) Pharmacist duties;

(3) Pharmacy intern duties;

(7) Security requirements;

(8) Storage requirements.

4729-5-36 Course requirements in the administration of immunizations (Effective 6-21-09)

(A) A course in the administration of immunizations developed pursuant to division (B)(1) of

(i) Disease states associated with the immunization;

(ii) Type or nature of activity of the immunization;

(iii) Appropriate administration schedules;

(iv) Appropriate routes of administration;

(v) Appropriate injection sites;

(vi) Appropriate dosages;

(viii) Appropriate patient populations;

(ix) Precautions and contraindications;

(x) Proper storage requirements for the immunization.

(c) A review of sterile technique in injectable dosage preparation and administration.

(d) A minimum of one hour of instruction and physical participation in administration

(f) A review of the proper procedures for accidental needle sticks.

4729-5-37 Protocols for the administration of immunizations (Effective 6-21-09)

(a) Name and strength;

(b) Precautions and contraindications;

(c) Intended audience or patient population;

(d) Appropriate dosage;

(e) Appropriate administration schedules;